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CHAPTER 1
Introduction

I.

Physiological and immune functions of the lung

The lung is an internal organ that is constantly exposed to the external environment. It is
also frequently targeted by infectious pathogens. The physiologic function of the lungs are
critical for good health and collateral tissue damage is detrimental, which presents an
immunologic dilemma for the host. While one of the most crucial functions of the lung is to
serve as the organ of gas exchange, it also has a major role in mediating host defense (1).
Breathing (ventilation) is the physiologic aspect of respiration, the means of gas
exchange in lungs. Carbon dioxide exchange (CO2) is produced during the oxidation of food
molecules and is exchanged for oxygen (O2) found in outside air. Fresh air is moved into and out
of the airways through the trachea and into the bronchi by convection of the air. Bronchioles
terminate into alveoli, where subsequent movement of gases between alveoli and blood in
pulmonary capillaries are mediated by the random movement of O2 and CO2 molecules from
regions of high to low concentrations (2). The pulmonary interstitium contains elastic and
collagen fibers that confer the elasticity and structural integrity of lung tissues, and is rich in
fibroblasts. The interstitium separates the endothelium and epithelium of pulmonary tissue. The
pulmonary interstitium is a supportive structure composed of a thin layer of cells found between
alveoli. Growth of this fibrous tissue is responsible for pulmonary fibrosis that results in patients
experiencing breathing difficulty. A schematic of mammalian lung anatomy can be found in
Figure 1.1.
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The lung is an organ that can be divided into two major anatomical compartments: the
bronchoalveolar space, clinically and experimentally accessible by lavage, and all else
encompassed in the lung tissue (3). Under homeostatic conditions, alveolar macrophages account
for up to 95% of all leukocytes in the lungs bronchoalveolar air spaces, vastly out numbering
lymphocytes (1-4%) and neutrophils (~1%) (4).
The lung epithelium, including mucus and ciliated epithelial cells that line the bronchi
and bronchioles, serves as a physical barrier to protect from environmental insults such as
infectious agents and harmful particulate matter (5). Mucus traps potentially damaging particles
and transports them by action of the mucociliary escalator that covers the nose, bronchi, and
bronchioles. Antimicrobial surfactant proteins are able to opsonize bacteria. Respiratory
epithelium is capable of directly sensing pathogens and even releasing cytokines such as
interleukin-25 (IL-25), IL-33, and thymic stromal lymphopoietin (TSLP). These innate processes
inherent to the lung parenchyma are generally able to maintain the semi-sterility of the lungs
without the intervention of the conventional immune system.
The largest population of lung leukocytes at stead state are alveolar macrophages (6),
which are the major orchestrators of pulmonary immune and inflammatory responses. These
tissue-resident macrophages, also known as dust cells in reference to their function, are located
in alveolar spaces and are highly active given their position at an important boundary between
inside the body and the outside environment (7). Their role in the non-infected host is to repress
the induction of immune responses. Resident alveolar macrophages are constantly encountering
inhaled material due to their anatomical position; thus, it is critical to the health of the host that
these cells are kept in a relatively quiescent state and have an anti-inflammatory phenotype to
prevent collateral damage to the lung parenchyma in response to innocuous antigens and
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maintain homeostasis (7). This is apparent by the downregulation of the phagocytic cell
membrane receptor CD11b (8), which is a canonical surface marker on most macrophage subsets
typically used to identify macrophages. Instead, alveolar macrophages are identified
phenotypically by their co-expression of F4/80 and CD11c (9).
Neutrophils play an indispensable role in the innate immune response to lung infection as
they are the first cells recruited in injured tissues (10). Intriguingly, the lungs appear to play an
immunoprotective role by physical sequestration of activated neutrophils during inflammatory
conditions by filtering primed neutrophils from circulation and being a site for de-priming (11).
Whether this phenomenon is active or passive remains unknown. Regardless, it is interesting that
activated inflammatory cells would enter the lung for deactivation, highlighting the potent antiinflammatory force of the lung microenvironment.
Dysfunction of immunological processes in the lung results in injury to this organ, which
can be detrimental to the host’s viability and quality of life.
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Figure 1.1. Diagram of lung anatomy and cross-sections of bronchi, bronchioles, alveolar
ducts, and alveoli. A) Gross anatomy of the lung and thorax. B) Bronchial wall. C) Terminal
airway and alveoli. D) Alveolar structure. Richard M. Effros, Anatomy, development, and
physiology of the lungs. GI Motility online (2006).
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II.

Radiation-induced lung injury

A. Adverse effects of radiation therapy for lung cancer. Radiation therapy is defined as the
medical use of ionizing radiation to kill malignant cells and control tumor growth. It has become
the most important nonsurgical modality for the treatment of cancer, with nearly 1 million people
of the approximately 1.4 million who developed cancer receiving treatment with radiation in the
United States (American Society for Therapeutic Radiation Oncology). Radiation therapy is
advantageous over surgery, being that it is non-invasive and potentially organ preserving.
Additionally, radiation therapy is tremendously cost effective, as it only accounts for 5% of the
total cost of cancer care (12).
Radiation therapy utilizes ionizing radiation, which causes mitotic cell death followed by
tissue repair and remodeling (13). The severity of tissue damage depends on several factors,
including radiation dose, quality, fractionation, tissue radiosensitivity, and the repair and
repopulation capacity of the organ (14). The degree of radiosensitivity of an organ refers to its
relative susceptibility to ionizing radiation (15). The radiosensitivity of a tissue is directly
correlated to the proliferative potential of its constituent cells and inversely proportional to the
degree of their differentiation. Due to the lack of regenerative capacity, the lung is one of the
most radiosensitive normal tissues in the body (16). The high radiosensitivity of the lung
parenchyma is the major dose-limiting factor in thoracic radiation therapy.
The therapeutic ratio of radiation therapy refers to the balance between the probability of
tumor control or cure and the risk of normal tissue complications. The probability of curing a
tumor increases with increasing radiation dose (17). However, it is an unavoidable consequence
that normal tissue will be included in the radiation field. Thus, a fundamental and ongoing
problem of radiation therapy is that the desired anti-tumor effect is coupled with injury to
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surrounding, otherwise normal and healthy tissues (Figure 1.2). One promising strategy to
improve the therapeutic ratio of radiation therapy is to administer it in combination with a
radiation protector or mitigator, (see Chapter 1, Section IIE for current treatments of RILI).
Radiation-induced lung injury (RILI) to normal tissue is a major concern in non-small
cell lung cancer (NSCLC). Radiotherapy given concurrently with chemotherapy is the
conventional treatment for locally advanced NSCLC presenting as unresectable, stage III disease
in approximately 50,000 Americans per year. There is an associated overall 5-year survival rate
of 20%, emphasizing the need to improve the efficacy of concurrent chemo-radiotherapy (18,
19). High intensity radiotherapy could be more effective but the therapeutic ratio is limited by
lung tissue toxicity.
RILI was first described in 1898, shortly after Wilhelm Röentgen discovered x-rays and
Antoine Becquerel discovered radioactivity as various forms of radiation used to treat cancer
(20). The distinction between two distinct types of RILI was not made until 1925. Molecular and
cellular damage occur immediately after tissue exposure to ionizing radiation, yet the clinical and
physiopathological features are often delayed for weeks, months, or years after treatment. RILI
leads to compromised lung function, including diffusion and gas exchange, affecting the
breathing capacity of patients and their overall quality of life (21-23). Clinically significant RILI
occurs in about 30% of patients receiving thoracic irradiation for lung cancer (24), while
concurrent chemotherapy increases this incidence (25).
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Figure 1.2. Dose-response curve for radiation therapy. Radiation therapy treatment schedules
aim to maximize tumor cure while minimizing normal tissue toxicity. The dotted line represents
a theoretical dose associated with an optimal therapeutic outcome. The probability of normal
tissue damage increases with radiation dose. Adapted from Barnett, GC et. al. 2009, Joiner, M.C.
and Van Der Kogel, A.J. 2009.
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B. Radiation-induced lung injury: Early and late effects. It is important to make a distinction
both clinically and biologically between early and late radiation side effects to provide insight
towards the development of novel therapeutic interventions. Radiation pneumonitis occurs in the
acute phase, within 4-12 weeks after completion of radiation therapy (26). Clinically, patients
with pneumonitis present with shortness of breath, chest pain, cough, congestion and fever (27).
Radiation fibrosis occurs in the late phase, develops within 6-12 months after the completion of
radiation therapy, and can continue to progress for over 2 years before becoming stable (26).
Patients may present in the clinic with progressive chronic dyspnea (i.e., difficulty breathing),
and radiologic findings which are consistent with lung fibrosis and include lung tissue retraction,
pleural thickening, volume loss, and tracheal deviation toward the irradiated region (28). Thus,
RILI is classically divided temporally, according to the time of symptom appearance, as either
the early, acute inflammatory phase or the late, chronic fibrotic phase. These two distinct yet
closely related phases of RILI are characterized by particular histologic lesions and may occur
sequentially or independently.
Radiation-induced pneumonitis and fibrosis is driven by a complex process involving an
early inflammatory process triggered by damage to lung parenchyma, epithelial cells, vascular
endothelial cells and stroma that involves induction of pro-inflammatory cytokines and
chemokines which recruit inflammatory immune cells in the lung tissue resulting in pneumonitis
and late fibrosis (23, 29, 30). Initially, oxidative injuries after radiation induce expression of proinflammatory cytokines. These ensuing cytokines subsequently mediate the recruitment of
inflammatory cells into the injured tissue. Infiltrating inflammatory cells are stimulated and
activated, producing additional mediators, resulting in a cytokine cascade (31, 32). The
expansion and perpetual activation of inflammatory cells, and components of the lung
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parenchyma, lead to clinical pneumonitis. Activated cells produce molecular mediators and
growth factors that affect the proliferation and gene expression of lung fibroblasts (33). This
process leads to increased collagen synthesis and deposition, eventually leading to the
development of lung fibrosis.
C. Cellular mediators of radiation-induced lung injury. The lung is composed of
approximately 50 distinct cells types (2). Rube et. al. first formally proposed a multicellular
cross talk hypothesis involving the interaction of a multitude of cells that reside in a given tissue
to explain the development and pathogenesis of radiation injury (34). According to this model,
all cells in the irradiated lung such as endothelial and epithelial cells as well as inflammatory
cells actively contribute to RILI. Alveolar epithelial cells consist of type I and type II
pneumocytes (Figure 1.1D). Type I pneumocytes cover more than 90% of the alveolar
epithelium surface. Type II pneumocytes secrete surfactant and regulate surface tension.
Radiation-induced apoptosis of type I pneumocytes leads to the proliferation of type II
pneumocytes, which reduces the regenerative capacity of the alveolar epithelium. In response to
radiation-induced injury and inflammatory stress, lung fibroblasts differentiate into
myofibroblasts and this turnover contributes to the formation of scar tissue through the
generation of collagen, fibronectin, and other ECM components by myofibroblasts (35). Early
radiation responses in the lung may be driven by activation or damage of lung epithelial or
endothelial cells, while fibroblasts are likely contributors to late radiation fibrotic responses. The
interaction of these lung cells with inflammatory cell subsets in the lung after radiation
undoubtedly plays an important role in the pathology and progression of RILI.
Studies carried out in immunocompromised mice lacking functional T and B cells
demonstrate that radiation pneumonitis and fibrosis occur in the absence of functional
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lymphocytes (36), indicating that cells of the adaptive immune system are not required for the
induction or promotion of RILI. Rather, innate immune cells appear to be the major contributors
to the pathology associated with radiation toxicities in the lung, with a particular emphasis on
macrophages.
Given the sheer abundance of macrophages in the lungs in the steady state, it is no
surprise that these cells are central players in inflammatory, immunoregulatory, and repair
processes. Alveolar macrophages exhibit a great capacity to functionally contribute to pulmonary
inflammation and anti-microbial defenses (37). In contrast, interstitial macrophages have been
shown to have more immunoregulatory roles in the maintenance of lung homeostasis and during
pathologic conditions (38). It is interesting to note that after thoracic irradiation, macrophages
are prominently found at inflammatory and fibrotic foci in the lungs (39).
Classically activated M1 macrophages are generated inflammatory cytokines (TNF-α,
GM-CSF, IFN-γ) M1 macrophages and mediate acute inflammation, kill intracellular microbes,
and participate in Th1 reactions. M2 macrophages can be generated through alternative
activation by IL-4, IL-13, IL-10, TGF-β, or immune complexes, and have an immunosuppressive
phenotype. M2 macrophages participate in Th2 and Treg reactions (40). M1 macrophages
produce NOS2, which generates reactive NO species, thus promoting inflammation. M2
macrophages produce Arg-1, which generates L-orthonine, a precursor of proline, from arginine
(41). Proline enhances collagen synthesis, thus promoting tissue repair and resolution of
inflammation (42). The M1 phenotype predominates during the acute inflammatory phase, and
then switches to M2 during wound-healing phase (43).
Neutrophils possess potent antimicrobial properties and are the first cells to be recruited
to sites of inflammation. Neutrophils are known to contribute to acute lung injury (44). However,
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a specific role for neutrophils in RILI has been unclear. Myeloperoxidase (MPO) is an abundant
constituent of activated neutrophils and its presence in tissues is a marker of neutrophil
recruitment (45). Increases in MPO expression and activity have been detected in irradiated
lungs (46, 47), suggesting that activated neutrophils contribute to mediating lung damage after
thoracic irradiation.
D. Molecular mediators of radiation-induced lung injury. Radiation disrupts endothelial and
epithelial cell barrier integrity by interrupting adherens junctions that bind cells together within
tissues. E-cadherin is an adhesion molecule expressed on epithelial cells (48). Normal expression
of lung E-cadherin is critical for the maintenance of tight junctions between epithelial cells and
for maintenance of normal barrier function of airway epithelium. Decreased E-cadherin
expression in the lung would be indicative of a disrupted epithelial barrier, which can result in
the recruitment of inflammatory cellular and molecular mediators and drive chronic
inflammation.
Direct killing of cells by ionizing radiation releases damage-associated molecular patterns
(DAMPs) into the extracellular milieu, stimulating an inflammatory response (49). Furthermore,
irradiation induces pro-inflammatory and chemotactic cytokine gene expression programs in
lung parenchymal cells, including leukocytes, fibroblasts, endothelial, and epithelial cells. These
molecular mediators including, IL-1β, IL-6, and TNF-α, can subsequently recruit inflammatory
cells to the injured tissue or influence the phenotype of resident leukocyte subsets already present
in the lung, stimulating susceptible cells to further produce cytokines. These levels fluctuate over
time during the radiation tissue damage response, producing a cyclic cytokine cascade, as
observed by cycles of increased and decreased cytokine release (30).
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During the process of a normal wound healing response, inflammation after tissue injury
is resolved and ECM breakdown products are removed. . In contrast, lung injury induced by
radiation leads to lung fibrosis, in which the inflammation is unresolved due to a process akin to
an aberrant wound healing response (30, 50). Lung fibrosis that occurs after thoracic radiation is
analogous to a “wound that won’t heal”, since regulatory feedback mechanisms are not observed,
resulting in inflammatory cells and myofibroblasts that remain constitutively active. These cells
in irradiated tissue therefore are perpetually receiving tissue repair signals.
Fibrogenesis and excessive ECM and collagen deposition are key contributors in the
development of late radiation effects and fibrosis in the lung. Fibrosis is an endpoint in response
to tissue injury that is characterized by the replacement of normal, functional tissue by collagenrich matrix (51). Chronic inflammation in the lung can lead to pulmonary fibrosis. Transforming
growth factor (TGF-β) is a pleotropic cytokine produced by numerous inflammatory,
mesenchymal, and epithelial cells (52, 53). TGF-β has a multitude of functions and has been
implicated in the formation of lung fibrosis (54). Several studies showed potential for TGF-β as a
serum marker of RILI (55-57); however, their findings were not confirmed by a subsequent
prospective study that evaluated plasma TGF-β levels (58). Strategies to target TGF-β for the
mitigation of radiation-induced pulmonary toxicity need to be tested prospectively in the clinic to
determine if inhibiting this pathway in humans is safe and effective.
E. Limitations of current management of radiation-induced lung injury. Management
strategies for RILI can be classified under the following three categories of intervention:
protection, mitigation, and treatment (59). Protectors are designed to prevent normal tissue
damage and are administered prior to radiation, while mitigators and treatments are given during
or after a course of radiation therapy, or after RILI symptoms emerge (60). Despite decades of
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research, there is a disproportionately low number of radioprotectors presently in use and they
are limited to selected cancers. Several therapies have been investigated to minimize
radiotoxicity yet there is currently no known optimal radioprotective therapy for RILI,
particularly for the treatment of late fibrosis (22, 61). Limitations include the safety profile of
these agents along with the risk of tumor protection from a desired radiation effect.
Prospective controlled studies in humans have not been performed to determine the
efficacy of potential therapies for RILI. Steroid therapy is the current treatment for symptomatic
patients with subacute onset of RILI, and unfortunately its use is accompanied with extensive
side effects (62, 63). Glucocorticoids, antibiotics, or heparin may be administered
prophylactically despite a lack of efficacy in reducing the incidence of radiation pneumonitis (24,
25, 62), and symptoms tend to recur when therapy is discontinued. Furthermore, patients with
established radiation-induced fibrosis are unlikely to benefit from glucocorticoid therapy (64).
A key feature of wound healing and fibrosis, regardless of the cause, is remodeling of the
extracellular matrix (ECM) and excessive deposition of the ECM component collagen (65).
Accordingly, therapies that inhibit collagen synthesis such as colchicine, penicillamine,
interferon-gamma (IFN-γ), or pirfenidone, were thought to potentially alter the progression of
radiation fibrosis. Currently, it is unknown whether drugs that inhibit collagen synthesis and
deposition will slow further fibrosis.
Pentoxifylline has been studied as a treatment for radiation fibrosis. It is a methylxanthine
derivative that improves microvascular blood flow and inhibits platelet aggregation. In an open
label drug trial, the effect of oral pentoxifylline was evaluated in patients with soft tissue postirradiation fibrosis of the neck, chest wall, pelvis, or extremities (66). Although pentoxifylline
has immunomodulatory properties mediated by inhibition of pro-inflammatory cytokines (67),
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particularly TNF-α and IL-1 (68, 69), it was found to be ineffective in the treatment of chronic
radiation-induced fibrosis. A separate randomized double-blind study of pentoxifylline taken
orally 3 times a day concomitantly with radiation therapy showed a modest benefit in the
prevention of radiation-induced pulmonary toxicity, in a small sample size of 16 lung cancer
patients (70).
Angiotensin converting enzyme (ACE) inhibitors are a class of drugs primarily used to
treat hypertension and congestive heart failure by relaxing blood vessels, leading to reduced
blood pressure and decreased oxygen demand from the heart (71). Captopril, an ACE inhibitor,
reduced radiation-induced lung fibrosis in a preclinical rat model (72). In a retrospective study
that included patients that received radiation therapy for lung cancer, ACE inhibitors reduced
clinically significant acute radiation pneumonitis compared to matched patients not on ACE
inhibitors (73). Prospective studies must follow up to confirm these findings. Whether ACE
inhibitors also decrease radiation fibrosis remains to be clinically investigated.
Amifostine, known as WR-2721 or the trade name Ethyol®, is a radioprotector currently
being investigated as a therapy to reduce the incidence and severity of radiation pneumonitis in
normal tissues. It was first developed by the Anti-Radiation Drug Development Program of the
U.S. Army in the 1960’s as a potential agent to protect against ionizing radiation exposure (74).
Amifostine has been shown to eliminate free radicals in tissues generated by radiation therapy,
resulting in cytoprotection, and is currently the only radioprotector in clinical use (61). The
results of randomized studies revealed that this drug is particularly promising for radioprotection
in patients being treated for head and neck cancers. It is approved for xerostomia (i.e., dry
mouth) in patients following head and neck irradiation (75).
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Amifostine is an inactive prodrug that is dephosphorylated by alkaline phosphatase in
normal endothelium to the active thiol metabolite, WR-1065, which can act as a free radical
scavenger. The decreased vascularity of the tumor and the differential expression of alkaline
phosphatase in normal versus malignant tissues contribute to the selective cytoprotective effects
of amifostine. In a study evaluating a protective role of amifostine for pulmonary toxicities in
patients with stage II or III NSCLC receiving concurrent chemoradiotherapy, amifostine
significantly reduced acute pneumonitis in patients receiving radiation therapy (23% vs 3.7%,
p=0.037) (76). Unfortunately, disadvantages of amifostine include the need for daily intravenous
infusions, prohibitive price, and associated systemic effects such as severe nausea and vomiting
which resulted in treatment discontinuation in over 20% of patients enrolled in a phase III
randomized trial in head and neck cancer (77).
Understanding the cellular and molecular mechanisms of the inflammatory processes
involved in RILI may lead to the development of more effective prophylactic and therapeutic
interventions.
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III.

Soy isoflavones

A. Beneficial properties of soy. Plant-based foods are a multifaceted assortment of chemicals,
including both nutrients and biologically active compounds that are nonnutrients (78). The latter
are referred to as nutraceuticals or phytochemicals. There are records of soy use in China that
date back to the eleventh century B.C., although the plant did not reach Europe and the United
States until the 18th century (National Cancer Institute). The soybean is a versatile plant that can
be processed into a variety of products for dietary consumption including soy milk, miso, tofu,
soy flour, and soy oil (79). Soy foods contain many phytochemicals that may have health
benefits, including phytic acid, sterols, saponins, isoflavones, and lignans (80). Among these, soy
isoflavones have been the significant focus of research due to their possession of a plethora of
biological activities including anti-inflammatory, antioxidant, chemopreventative, and antitumor
effects.
Isoflavones are always present in significant amounts in soybeans and serve an important
physiologic function for the host. Isoflavones in soybean plants promote infection of plant roots
by beneficial, mutualistic soil bacteria (81). Soy isoflavones facilitate a symbiotic relationship
between soybean and Rhizobium bacteria by inducing the transcription of nodulation genes
expressed in the Rhizobium bacteria. This results in the rhizobia inducing the formation of
nodules on roots of soybean plants (82). Rhizobia also fix nitrogen which the plant can then use
for growth.
Soy isoflavones are known as phytoestrogens due to their similarity in structure to the
human female hormone 17-β-estradiol, and their ability to bind estrogen receptors in vitro and
induced estrogen-like effects in vivo (83). However, phytoestrogens have relatively weak
estrogen activity compared to animal estrogens (84), and isoflavones have a greater affinity for
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estrogen receptor beta (ER-β) than for estrogen receptor alpha (ER-α) (85). Phytoestrogens such
as soy isoflavones can also have estrogen receptor antagonist activity by interacting with and
blocking binding sites from endogenous estrogen (86). Their mode of biological action involve
both ER-dependent and ER-independent mechanisms. Genistein is the most abundant and
bioactive soy isoflavone (87). Other isoflavones found in soybeans include daidzein and
glycitein. Isofavones are also beneficial to the soybean plant as a survival mechanism during
times of stress due to the antioxidant, antimicrobial, and antifungal properties of these
phytoestrogens (88).
The combined effect of multiple isoflavones in preventing or treating cancer compared to
that of a single isoflavones has been investigated in preclinical studies, by our group and others,
indicating that administering mixtures of isoflavones increases effectiveness of the individual
compounds (89, 90). Isoflavones act as chemopreventative agents as suggested by
epidemiological studies (91-93), and a high-soy diet is associated with a decreased risk of
prostate cancer (94-96).
B. Molecular structures and metabolism. Soy isoflavones are diphenolic compounds that
share a structural similarity to estrogen, as presented in Figure 1.3 (adapted from (97) and (98)).
These compounds possess a variety of biological activities including the ability to act as an
antioxidant. Genistein, in particular, is a potent tyrosine-specific kinase inhibitor (99). This leads
to its chemoprotectant activities against chronic inflammatory disorders, cancers, and
cardiovascular disease.
Isoflavones are present in soybeans primarily as β-glucosides, their inactive form,
becoming active in the plant when the sugar molecule is cleaved. Soy isoflavones are quite heatstable, thus cooking soy foods does not change the total isoflavone content or nutraceutical value
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(100). Glycosidic isoflavones are not readily bioavailable in humans due to the sugar-binding
moiety that prevents their crossing through enterocytes, and hydrolysis is required for gut
absorption and bioavailability. After oral uptake, isoflavones are unconjugated and absorbed by
the gastrointestinal tract, and can be detected in plasma as soon as 30 minutes after the
consumption of soy products (101). Intestinal β-glucosidases catalyze hydrolysis of the sugar
moiety and the gut microflora metabolize the aglycones (102). Unconjugated aglycones are
produced after hydrolysis, which can be further metabolized into p-ethyphenol (from genistein)
and equol (from daidzein). During metabolism, formononetin and biochanin A are demethylated
to daidzein and genistein, respectively (Figure 1.3). The resulting metabolite levels can differ to
a great extent and depend on the individual microflora. The majority of the absorbed aglycones
are immediately re-conjugated and have two possible fates: enter circulation to be available to
the body or return to the intestinal lumen through the portal circulation to be absorbed in the
large intestine (103). Conjugated isoflavones are no longer functional or bioactive. Only 1% of
the isoflavones in human plasma are circulating in the active, aglycone form; they are
predominantly inactive glucuronides (75%) and sulfates (24%), named in reference to their
conjugates. Isoflavone levels in plasma reach a maximum concentration by 6 hours following
soy product consumption (101). Once these compounds are in the body they are re-conjugated to
glucuronides and excreted in the urine.
Levels of serum isoflavones in our murine studies following treatment with 1 mg/day of a
mixture of soy isoflavones reflected typical in vivo metabolism with significant levels of
daidzein (1.6 μM) and genistein (1.7 μM) (90). These levels are comparable to plasma
concentrations of 1–4 μM soy isoflavones measured in Asian populations consuming foods rich
in soy isoflavones, in contrast to levels of 10-30 nM found in Western populations (36).
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Figure 1.3. Molecular structures of soy isoflavones and endogenous 17-β-estradiol
(estrogen). (A). Structure of isoflavone backbone. (B). The major isoflavones in soybean are
genistein (50%), daidzein (40%), and glycitein (10%). (C). Biochanin A and formononetin are
derivatives of genistein and daidzein, respectively. Equol is a breakdown product of daidzein,
however only ~30-50% of people have the intestinal microbiota to produce equol. (D). Structure
of the primary female sex hormone, estrogen. Adapted from Kurosu 2011 (97) and Day et. al.
2002 (98).
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C. Soy isoflavones and the immune system. The most extensively studied isoflavone in
respect to effects on the immune system is genistein, which was shown to regulate immune
function (104). Genistein has been shown to have strong immune modulatory effects on
macrophages, via inhibition of the production of TNF-α (105). Genistein may also downregulate
cytokine-induced pro-inflammatory pathways in human brain microvascular endothelial cells
(106), and soy isoflavones have been shown to have anti-inflammatory mechanism via
modulation of leukocyte-endothelial cell interactions in a study of atherosclerosis (107).
Nuclear factor κB (NF-κB) activation is a molecular common denominator between
inflammation and cancer (108). This transcription factor is constitutively active in a large
number of cancers and is critical for tumor cell survival. Our lab has previously shown in tumor
cells that soy isoflavones target critical survival pathways that are upregulated and constitutively
activated in cancer cells, including NF-κB, which are responsible for the transcription (109). In
contrast, normal cells do not constitutively express activated NF-κB, and activation of this
transcription factor is important for the expression of pro-inflammatory gene programs.
Differential expression of soy isoflavones targets in tumor cells versus normal cells is a potential
mechanism of specificity for soy effects in cancer models.
D. Controversy associated with the use of phytoestrogens. Soy isoflavone intake among
people in the Western world (0.15-1.7 mg per day) (110-112) is about 100-fold less than that of
Asians (15-50 mg per day) (113-116). The incidence of breast and prostate cancers is lower
among Asians compared to people in the Western world (117), thus soy consumption appears to
be related to the decreased risk of cancer recurrence and/or mortality.
The first report linking isoflavones and cancer was almost 30 years ago when it was
shown that genistein is a potent inhibitor of multiple protein tyrosine kinases relevant to cancer
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cell growth and proliferation (118). The use of soy isoflavones in patients with or at risk of
developing breast cancer was proposed when they were shown to inhibit the proliferation of
several types of cancer cells (119).
Interest in isoflavone metabolism was piqued when it was realized that phytoestrogens
are capable of disrupting normal endocrine function and their estrogenic properties were
connected to infertility in animals (120, 121). A well-documented incident involves an outbreak
of infertility in sheep in Australia that were grazing red clover that contained a high percentage
of the isoflavone formononetin, which was being metabolized into equol by intestinal bacteria
(122). When these sheep were switched to a genetically modified clover lacking isoflavones the
infertility was ameliorated. Interestingly, it has been hypothesized that phytoestrogens may have
evolved in plants as a protective mechanism by interfering with reproduction of grazing animals
(97). Despite the detrimental effects of soy isoflavones reported in animal fertility, the effects of
isoflavones on human reproductive function have not been sufficiently identified. An explanation
for this discrepancy may lie in the vast difference in isoflavone exposure between animals and
humans. The amount of isoflavones in the clovers consumed by the Australian sheep that caused
their infertility was estimated to be about 20-100 g per day, which is up to 2000-fold higher than
the amount of isoflavones achievable by humans consuming a high soy isoflavone diet (15-50
mg per day) (123, 124). Therefore, it is not likely that humans on a diet with a typical soy intake
will achieve comparable levels of biologically active isoflavones to impact fertility, despite the
ability of phytoestrogens to disrupt the endocrine system in animals and cause infertility.
There have been numerous prospective epidemiologic statues that have evaluated the
impact of soy intake on the prognosis of breast cancer survivors after diagnosis (Table 1) (125131). A recent meta-analysis of 35 studies in pre- and/or post-menopausal women reporting an
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association between soy isoflavones intake and breast cancer risk found that there is indeed no
harmful association between intake of soy isoflavones and breast cancer (132). Taken together,
the overwhelming evidence to date suggests that soy foods are not harmful for breast cancer
survivors to consume. There is no evidence-based basis for advising breast cancer patients
against the consumption of soy foods, further supporting the safety of soy isoflavones.
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Table 1. Description of epidemiologic studies evaluating the effects of soy intake on breast
cancer prognosis. Prospective studies in different countries have evaluated the impact of postdiagnosis soy intake on the prognosis of breast cancer survivors and have overwhelmingly
concluded that soy isoflavones consumption in breast cancer survivors is safe, and even
beneficial in some instances. Table adapted from Messina et. al. It’s Time for Clinicians to
Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients. Oncology
(2013) (133).
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E. Soy isoflavones for the treatment of radiation injury. We have previously demonstrated in
mice receiving a single high dose of thoracic irradiation (Figure 1.4) that soy isoflavones have
the dual capability of protecting normal lung tissue from radiation injury while simultaneously
enhancing radiation damage in the tumor (36, 134, 135). In a pre-clinical lung cancer model,
supplementation with a mixture of soy isoflavones (genistein, daidzein, and glycitein) given preand post-thoracic irradiation mitigated the vascular damage, inflammation and fibrosis caused by
high dose radiation injury to lung tissue suggesting that soy can alter the radiation-induced
inflammatory response (36, 134). In naïve mice, soy protected the lungs against adverse effects
of radiation including skin injury, hair loss, increased breathing rates, inflammation, pneumonitis
and fibrosis (135). The soy isoflavone genistein and the superoxide dismutase mimetic EUK-207
were observed to mitigate radiation-induced lung damage in naïve rats. These compounds
inhibited late occurring pulmonary fibrosis and reduced levels of activated macrophages and
TGF-β1 expression (136).
These outcomes in naïve mice corroborated our findings in lung tumor models and
provided further evidence for a radioprotective effect of soy isoflavones. It is important to note
that soy isoflavones also sensitized cancer cells to radiation both in vivo and in vitro in preclinical tumor models of lung cancer, demonstrating a differential effect of radioenhancement on
lung tumors with simultaneous radioprotection of normal lung tissue (36, 134, 137).
In support of a clinical application of soy isoflavones for radioprotection in lung cancer,
the use of soy isoflavones as radioprotectors was found to be safe in human clinical trials (138).
Prostate cancer patients receiving radiation therapy and soy tablets had reduced radiation toxicity
and resulted in improved urinary, sexual and gastrointestinal functions (139). These findings
suggest that soy isoflavones used as a complementary intervention to radiotherapy for lung
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cancer could potentially reduce lung toxicity and provide improved therapeutic benefit to
patients. While the anti-oxidant and disease preventative effects of a soy-rich diet have been
investigated, an immune-mediated mechanism of radioprotection by soy isoflavones in normal
tissues remains to be elucidated.
Alteration of the host immune response by radiation therapy through the triggering of a
potent inflammatory response is a key contributor to the tissue-damaging pathology of RILI. Soy
isoflavones may inhibit this inflammatory process or promote tissue repair. The research
objective of this dissertation is to investigate radioprotection mediated by soy isoflavones in
normal lung tissue by dissecting the radiation-induced inflammatory response (Figure 1.5). The
clinical goal is to improve the therapeutic ratio of high-dose radiation therapy on the tumor target
and reduce the radiation dose-limiting toxicity of radiation therapy to the normal lung.
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Figure 1.4. Selective delivery of high-dose radiation therapy to lungs. Radiation is delivered
to the thoracic cage comprising the whole lung. Three anesthetized mice, in jigs, are positioned
under a 6.4 mm lead shield with 3 cut-outs in an aluminum frame mounted on the X-ray machine
to permit selective irradiation of the lung in 3 mice at a time, as previously described (134). The
radiation dose to the lung and the scattered dose to areas of the mouse outside of the radiation
field are carefully monitored. To minimize backscattering of radiation, the bottom of the
aluminum frame that holds the jigs was hollowed out and the backplate of the jig was thinned to
1.6mm thickness. Under these conditions and the lead shielding, the X ray dose to the shielded
regions was reduced to 1% of the dose to the irradiated field. The dose rate was 101 cGy/min and
half value layer was 2 mm Cu. Photon irradiation was performed at a dose of 10 Gy with a
Siemens Stabilipan X-ray set (Siemens Medical Systems, Inc., Erlangen, Germany) operated at
250 kV, 15 mA with 1 mm copper filtration at a distance of 47.5 cm from the target.
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Figure 1.5. Experimental design and treatment strategy. Mice were pre-treated with oral soy
isoflavones each day for 3 days at a dose of 5mg/day (equivalent to 250mg/kg). Then, the lung
was selectively irradiated with 10 Gy. Soy treatment was continued on a daily basis for 5 more
days at 5mg/day. Then mice were treated with a lower soy dose of 1mg/day (equivalent to
50mg/kg), given daily 5 days a week for up to 18 weeks. The rationale for giving a higher dose
of soy isoflavones for pre-treatment and just after radiation is to optimize the effect of soy, based
on previous studies (36, 140). At different time points after radiation, separate mice from each
treatment group were either processed for flow cytometry studies or homogenized for ELISA,
snap frozen for western blot, or mice were used to fix lungs in situ with formalin for histology
studies.
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CHAPTER 2
Soy Isoflavones Promote Radioprotection of Normal Lung Tissue by Inhibition of
Radiation-Induced Activation of Macrophages and Neutrophils

ABSTRACT

Thoracic radiotherapy for the treatment of lung cancer is limited by morbidity-associated
toxicities. Normal lung tissue damage after radiation therapy results from a chronic inflammatory
response, leading to pneumonitis and fibrosis. Soy isoflavones mitigate inflammatory infiltrates
and radiation-induced lung injury, but the cellular inflammatory mediators altered during
radioprotection are unknown. Oral treatment with a mixture of soy isoflavones (genistein,
daidzein, and glycitein) before and after administration of a high dose thoracic radiation at 10 Gy
led to a reduction in infiltration and activation of alveolar macrophages and neutrophils in both
the bronchoalveolar and lung parenchyma compartments. Soy treatment protected F4/80+CD11cinterstitial macrophages which are known to play a regulatory role in inflammation and are
decreased by radiation. Furthermore, soy isoflavones reduced the levels of nitric oxide synthase2 (NOS2) expression but increased arginase-1 (Arg-1) expression in the lung parenchyma after
radiation, suggesting a switch from pro-inflammatory M1 macrophage to an anti-inflammatory
M2 macrophage phenotype. Soy also prevented the influx of activated neutrophils in lung caused
by radiation. The modulation of macrophage and neutrophil responses to radiation by soy
isoflavones could play a role in the resolution of radiation-induced chronic inflammation in the
lung.
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INTRODUCTION

Radiation pneumonitis is caused by an early inflammatory process triggered by damage
to lung parenchyma, epithelial cells, vascular endothelial cells and stroma. This process involves
induction of pro-inflammatory cytokines and chemokines which recruit inflammatory immune
cells to the lung tissue resulting in pneumonitis and late fibrosis (29, 30, 141). Early acute
pneumonitis occurs by 2-4 months after radiotherapy, while late chronic pneumonitis manifests
clinically over 6-24 months (21, 23). At late stages, radiation-induced pulmonary fibrosis results
from aberrant resolution of inflammation in contrast to classical wound healing processes (30).
These adverse events after radiotherapy affect patients’ breathing and their quality of life.
Various strategies to decrease the extent of pneumonitis have been investigated but need further
research efforts (142).
We have reported in preclinical mouse models that supplementation of soy
isoflavones with thoracic irradiation mitigates radiation-induced inflammatory cytokines,
infiltration of inflammatory cells and fibrosis (36, 134, 135), but the cellular mediators of
radioprotection remain unclear. In Chapter 2, we investigate the role of macrophages and
neutrophils in the mitigation of radiation-induced inflammatory events by soy isoflavones in lung
tissue. Macrophages are recruited as a first response to radiation-induced damage in the tumor
microenvironment or in normal tissues (143). Macrophages play distinct roles in the early versus
late stages of inflammatory response (144-146). Monocytes can differentiate into functionally
different macrophage subsets. Inflammatory cytokines (TNF-α, GM-CSF, IFN-γ) generate
classically activated M1 macrophages that mediate acute inflammation and participate in Th1
reactions (40). M2 macrophages can be activated by IL-4, IL-13, IL-10, TGF-β, or immune
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complexes, participate in Th2 and Treg reactions, and promote tumor growth and fibrosis (43,
147). M1 predominates during acute inflammation, and then switches to M2 during the woundhealing phase at later stages (43). We tested whether soy influences macrophage skewing to M1
or M2 subsets, and if this altering of macrophage phenotypes could dictate normal lung response
to radiation-induced damage.
Activation and infiltration of neutrophils is a hallmark event in the progression of acute
lung injury (44), and have been shown to be involved in radiation-induced alveolitis (46).
Therefore, the effect of soy isoflavones on infiltration and activation status of neutrophils was
studied after radiation to the lungs. Our findings suggest that soy can inhibit the infiltration and
activation of macrophages and neutrophils induced by radiation in lung parenchyma. Radiation
induced a pro-inflammatory M1 macrophage phenotype in lungs, while mice receiving soy
isoflavones and radiation switched to an anti-inflammatory M2 macrophage subtype. These data
indicate that soy isoflavones modulate the cellular mediators of the inflammatory response
induced by radiation.
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MATERIALS AND METHODS

Mice
Female BALB/c mice (Harlan, Indianapolis, IN) 5-6 weeks old, were housed and handled
in animal facilities accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care. The animal protocol was approved by Wayne State University
Institutional Animal Care and Use Committee.

Soy isoflavones
The soy isoflavone mixture G-4660 used is a pure extract of 98.16% isoflavones from
soybeans consisting of 83.3% genistein, 14.6% daidzein and 0.26% glycitein (manufactured by
Organic Technologies and obtained from the National Institutes of Health [NIH], Bethesda,
MD). The soy isoflavone mixture was dissolved in DMSO and mixed with sesame seed oil at a
1:20 ratio just prior to treatment to facilitate gavage and avoid irritation of the esophagus by
DMSO (36, 134, 135).

Lung irradiation
Radiation was delivered to the thoracic cage comprising the whole lung. Three
anesthetized mice, in jigs, were positioned under a 6.4 mm lead shield with 3 cut-outs in an
aluminum frame mounted on the X-ray machine to permit selective irradiation of the lung in 3
mice at a time, as previously described (134). The radiation dose to the lung and the scattered
dose to areas of the mouse outside of the radiation field were carefully monitored. To minimize
backscattering of radiation, the bottom of the aluminum frame that holds the jigs was hollowed
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out and the backplate of the jig was thinned to 1.6mm thickness. Under these conditions and the
lead shielding, the X ray dose to the shielded regions was reduced to 1% of the dose to the
irradiated field. The dose rate was 101 cGy/min and half value layer was 2 mm Cu. Photon
irradiation was performed at a dose of 10 Gy with a Siemens Stabilipan X-ray set (Siemens
Medical Systems, Inc., Erlangen, Germany) operated at 250 kV, 15 mA with 1 mm copper
filtration at a distance of 47.5 cm from the target.

Experimental design
Mice were pre-treated with oral soy isoflavones each day for 3 days at a dose of 5mg/day
(equivalent to 250mg/kg). Then, the lung was selectively irradiated with 10 Gy. Soy treatment
was continued on a daily basis for 5 more days at 5mg/day. Then mice were treated with a lower
soy dose of 1mg/day (equivalent to 50mg/kg), given daily 5 days a week for up to 18 weeks. The
rationale for giving a higher dose of soy isoflavones for pre-treatment and just after radiation is
to optimize the effect of soy, based on previous studies (36, 140). At different time points,
separate mice from each treatment group were either processed to harvest bronchoalveolar
lavage (BAL) fluid for differential cell counting and lungs for flow cytometry studies or snap
frozen for western blot, or mice were used to fix lungs in situ with formalin for histology studies
as detailed below.

Analysis of immune cells by differential cell counting in BAL fluid and flow cytometry on
single-cell suspension from lungs
BAL was performed prior to lung resection at 1, 8, 12, and 18 weeks after irradiation. To
obtain BAL fluid, phosphate-buffered saline (PBS) was gently instilled into the lungs and
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withdrawn through an incision of the trachea. The BAL fluid samples were centrifuged at 1500
rpm for 5 minutes at 4° C and supernatant was discarded. Cells were resuspended in media and
loaded onto slides using a cytospin centrifuge (Cytospin 3 Cell Preparation System, Thermo
Shandon, UK). Cell preparations were stained using a DiffQuik staining kit (IMEB Inc., San
Marcos, CA,) and differential cell counts of leukocyte subsets were performed by counting at
least 300 nucleated cells (148).
Following collection of BAL fluids, the same mice provided the lungs for flow cytometry
studies. Lungs were excised, minced, and digested with 0.4 mg/mL collagenase IV for 45
minutes at 37° C. Digested lungs were passed through a wire mesh, then a 0.7 μm nylon mesh.
Red blood cells were removed by incubating in red blood cell lysis buffer for 2 minutes at room
temperature. Single-cell suspensions obtained from the lungs were incubated with Fc receptorblocking antibody (eBioscience, San Diego, CA) prior to staining to reduce non-specific binding.
For morphological characterization of lung leukocytes, cells expressing the pan-leukocyte
marker CD45 were sorted by fluorescence-activated cell sorting (FACS) using a BD
FACSVantage SE (BD Biosciences). CD45+ cell subsets were gated according to cell size
[forward scatter (FSC), x-axis] and granularity [side scatter (SSC), y-axis]. Cell subsets obtained
from each gate were spun onto slides using a cytospin (Thermo Shandon, Pittsburgh, PA), and
stained using a DiffQuik staining kit (IMEB Inc., San Marcos, CA). To determine the phenotype
of immune cells, cells were immunostained using a 5-color fluorophore combination of
fluorescent antibodies consisting of CD45-APC, CD11b-FITC, F4/80-PE, CD11c-APCeFluor780, and Ly6G-PerCp-Cy5.5 (eBioscience). Fixable viability dye eFluor 450
(eBioscience) was used to exclude dead cells from analysis. Cells were analyzed by flow
cytometry using a BD LSR II flow cytometer (BD Biosciences, San Jose, CA) in the
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Microscopy, Imaging and Cytometry Resources Core at Wayne State University School of
Medicine, followed by analysis on FlowJo v10 software (Tree Star Inc., Ashland, OR).

Immunohistochemistry (IHC)
Mice were sacrificed and lungs were intratracheally instilled with 10% buffered formalin
and resected, embedded in paraffin, and sectioned. Sections were blocked with IHC Tek
Antibody Diluent (IHC World, Woodstock, MD) then incubated with primary purified
monoclonal antibodies directed against F4/80, nitric oxide synthase 2 (NOS2), arginase-1 (Arg1), Gr-1 (Ly6C/Ly6G), and myeloperoxidase (MPO) (Abcam, Cambridge, UK) overnight at 4°
C. Lung sections were then incubated with biotinylated secondary antibodies (Vector Labs,
Burlingame, CA) at 1:300 for 1 hour at room temperature. Staining was amplified with the
avidin-biotin system Vectastain ABC Reagent Kit (Vector Labs) and visualized with the Vector
DAB Substrate Kit for peroxidase (Vector Labs). Sections were counterstained with IHC-Tek
Mayer’s Hematoxylin (IHC World, Woodstock, MD) and mounted with Permount mounting
media (Electron Microscopy Sciences, Hatfield, PA). Macrophage and neutrophil infiltrations in
the lung tissue after radiation were evaluated on a Nikon E800 microscope (Nikon Inc., Melville,
NY). Quantitation of the number of F4/80+ alveolar macrophages and measurement of the cell
areas were performed using ImageJ software (NIH, Bethesda, MD) in 10 fields of 40x per slide.
For quantitation of overall level of staining, whole slide imaging was performed using a slide
scanner and DensitoQuant analysis (3D Histech). The percentage of positive area was calculated
as the total number of positive pixels divided by total number of pixels.

35

Preparation of lung tissue protein lysates and western blot analysis
Mice were sacrificed at 12 weeks post-irradiation. Lungs were resected and snap frozen.
To prepare lung tissue protein lysates, frozen lungs were thawed, weighed, and homogenized in
10% w/v of lysis buffer using a gentleMACS tissue dissociator (Miltenyi Biotec, Bergisch,
Germany). The suspension was centrifuged at 4000 x g for 5 minutes at 4°C and the protein
extracts were frozen at -80°C until analysis. For western blot analysis, total lung protein extracts
(50 µg) were loaded and separated on 10% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to Whatman membranes (GE Healthcare Life
Sciences, Pittsburgh, PA). Membranes were incubated with anti-myeloperoxidase (MPO)
antibody (Abcam, Cambridge, MA; 1:1000) overnight at 4°C. Membranes were washed and
incubated with horseradish peroxidase-conjugated secondary antibody (Vector Labs, 1:2000) at
room temperature for 1 hour. Immunoreactive protein bands were visualized by SuperSignal
West Pico Chemiluminescent Substrate (Thermo Scientific, Waltham, MA) and captured on a
digital imaging system (Fotodyne Inc., Hartland, WI). Membranes were re-probed with anti-β-

actin Ab as a loading control (137).

Statistical analysis
Data are expressed as mean ± SEM. Comparisons between means of two treatment
groups were analyzed by two-tailed unpaired Student’s t test using GraphPad Prism version 6.0
software (GraphPad Software Inc., San Diego, CA). A value of p<0.05 was considered
statistically significant.
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RESULTS

Effect of radiation and soy isoflavones on immune cell subsets recovered from
bronchoalveolar space. We previously demonstrated that soy isoflavones decreased the extent
of inflammatory infiltrates induced by radiation in lung tissues (36, 134, 135). To identify the
nature of inflammatory infiltrates in lungs induced by radiation and the effect of soy isoflavones
on these cells, we first analyzed immune cell subsets recovered from bronchoalveolar lavage
(BAL) (148). Mice were pre-treated with soy isoflavones for 3 days, and then received 10 Gy
irradiation administered to the whole lung. Soy treatment was continued for 5 days/week for up
to 18 weeks and BAL fluids were harvested at early and late time points post-radiation, including
1, 8, 12 and 18 weeks after radiation. Differential cell counts to identify the morphology of
immune cells were performed and the percentages of macrophages, neutrophils, and
lymphocytes were calculated (Figure 2.1). Activated macrophages presented a morphology of
enlarged foamy cells (Figure 2.1A, inset) that was clearly distinct from non-activated small
macrophages and were counted separately. Alveolar macrophages constituted 80% to 90% of
cells recovered from BAL fluids, and the majority presented as small non-activated macrophages
in control BAL (Figure 2.1). Soy did not alter the morphology of these macrophages. In contrast,
as early as one week after radiation, there was a significant decrease from 90.7±0.8% to
24.1±2.9% in small macrophages compared to control (p<0.0001) with a concomitant significant
increase from 9.1±0.7% to 75.8±3.0% in enlarged foamy activated macrophages (p<0.0001)
(Figure 2.1A). This trend was consistently observed at later time points of 8, 12 and 18 weeks
after radiation (Figure 2.1B, C, D). The ratios of activated versus non-activated macrophages
were reversed in BAL fluids from mice treated with radiation and soy. There was a significant
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increase in non-activated macrophages associated with a concomitant decrease in activated
enlarged foamy macrophages (p<0.01) that was consistently observed at 8, 12 and 18 weeks after
radiation and these ratios were comparable to the levels of control mice or mice treated with soy
alone. For example, at 18 weeks after radiation, there was a significant increase in the percentage
of enlarged, foamy macrophages to 79.0±6.7% compared with 14.6±5.3% in control (p=0.0003)
(Figure 2.1D). Soy significantly inhibited this radiation-induced increase to 33.1±8.3% compared
with radiation alone (p=0.0091) (Figure 2.1D). These data demonstrate that radiation induced a
rapid activation of macrophages that persisted for a long time as shown at 18 weeks. It should be
noted that soy consistently inhibited this activation of macrophages over time and the
macrophage morphology presented as small non-activated macrophages.
Whereas BAL fluids from healthy untreated mice have undetectable numbers of
neutrophils and lymphocytes, neutrophil counts showed a significant increase induced by
radiation at 12 weeks (19.0±2.1%, p<0.0001) which was decreased in radiation and soy
isoflavones-treated mice (8.4±3.2%, p<0.05) (Figure 2.1C). A measurable increase in BAL
lymphocytes was also observed after radiation; however, this increase was not seen in radiation
and soy-treated mice.
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Figure 2.1. Effect of soy isoflavones on immune cells obtained from BAL fluid at different time
points after radiation. BAL fluids were harvested at early and late time points post-radiation. At 1 week
(A), 8 weeks (B), 12 weeks (C), and 18 weeks (D) post-radiation, differential cell counts on BAL fluid
cytospins were performed and the percentages of macrophages, neutrophils, and lymphocytes were
calculated. The ratios of non-activated macrophages and enlarged, foamy activated macrophages (see
inset 1A), as well as those of neutrophils and lymphocytes, are shown from BAL fluid obtained from
treated and control mice. The data are presented as mean ± SEM (n = 3-5 mice/group/time point) and pvalues shown represent significant differences between radiation + soy compared to radiation alone.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, radiation compared to control or radiation + soy
compared to radiation alone.
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Flow Cytometry phenotypic analysis of immune myeloid cells infiltrating lung parenchyma
following treatment with radiation and soy isoflavones. Morphological analysis of the
immune cell subsets in the bronchoalveolar compartment revealed that radiation caused a switch
from non-activated to predominantly activated macrophages at 2-4 months after radiation,
whereas soy isoflavones prevented radiation-induced macrophage activation. To further analyze
the phenotype of myeloid cells involved in the radioprotection of lungs by soy isoflavones, we
have also analyzed the lung parenchyma compartment by processing lung tissue into single cell
suspensions and analysis of immune cell subsets by immunofluorescence staining and flow
cytometry.
Lung cell suspensions were immunostained using a 5-color fluorophore combination of
antibodies directed against CD45, CD11b, F4/80, CD11c, and Ly6G from lungs treated with soy,
radiation or radiation + soy at 12 weeks after radiation, as detailed in Materials and Methods.
Macrophages were gated based on differential expression of F4/80 and CD11c to analyze
interstitial macrophages (IM, F4/80+CD11c-) and alveolar macrophages (AM F4/80+CD11c+)
(Figure 2.2A) (149). Percentages of F4/80+CD11c- IM subsets showed a significant decrease in
interstitial macrophages induced by radiation compared to control (p<0.05), whereas this
treatment with soy isoflavones protected this population in irradiated lung tissue (p<0.05)
(Figure 2.2A). F4/80+CD11c+ AM subsets did not show difference between treatments (Figure
2.2A), in contrast to BAL findings that showed an increase in AM by radiation and decrease by
radiation + soy. The discrepancies between the evaluations of alveolar macrophages in the BAL
compartment versus the lung tissue compartment could be due to initial lavage of loose alveolar
macrophages to collect BAL fluid and subsequent processing of lungs for FACS. Therefore, we
assume that alveolar macrophages activated by radiation were washed out and recovered in the
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BAL resulting in no AM increase observed in lung tissue. Further analysis to resolve this
discrepancy is presented in IHC studies below (Figure 2.3). Neutrophils were gated by
expression of CD11b, and Ly6G/Gr-1 markers within the CD45+ population (Figure 2.2B) (150).
CD11b+Ly6G+ neutrophils in lungs are significantly increased after radiation compared to
control (p=0.01), however supplementation of soy to radiation did not significantly change the
percent of neutrophils (Figure 2.2B).
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Figure 2.2. Flow cytometry analysis of macrophages and neutrophils isolated from lung tissues. (A).
Interstitial and alveolar macrophages analysis. At 12 weeks after radiation, lungs from control (Con)
mice, and mice treated with soy (Soy), radiation (Rad) or radiation + soy (R+S) were dissociated into
single cell suspensions. Cells were stained with anti-CD45, anti-F4/80, and anti-CD11c fluorescent
antibodies to analyze interstitial (F4/80+CD11c-) and alveolar (F4/80+CD11c+) tissue macrophages within
CD45+ leukocyte populations by flow cytometry. Representative flow cytometry plots are presented,
showing the gating strategy of CD45+ myeloid lung cells for analysis of F4/80+CD11c- interstitial
macrophages (IM in pink rectangle gate) and F4/80+CD11c+ alveolar macrophage (AM in pink circle
gate). Percentages of F4/80+CD11c- IM subsets and F4/80+CD11c+ AM subsets within CD45+ cells are
shown for lungs from control and treated mice. The data are presented as mean ± SEM (n = 4-5
mice/group) and are representative of three separate experiments. (B). Analysis of CD45+CD11b+Ly6G+
neutrophils. Cells were stained with fluorescent anti-CD45, anti-CD11b, and anti-Ly6G to analyze
neutrophil subsets by flow cytometry. Representative flow cytometry plots are presented, showing the
gating strategy for analysis of CD11b+Ly6G+ neutrophils within CD45+ leukocyte populations.
Percentages of CD11b+Ly6G+ neutrophils within CD45+ cells are shown for lungs from control and
treated mice. The data are presented as mean ± SEM (n = 5 mice/group) and are representative of two
separate experiments. *p<0.05, radiation compared to control or radiation + soy compared to radiation
alone.
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Skewing toward anti-inflammatory M2 macrophage phenotype in lung tissue treated with
radiation and soy. The macrophages recovered from BAL fluids obtained from radiation + soytreated mice showed a morphology of small non-activated cells in contrast to the enlarged foamy
activated macrophages obtained from radiation-treated mice. To further study whether soy
inhibits the activation of macrophages induced by radiation, we investigated, in situ in the lung
tissues, macrophage subsets and their functional status in lungs treated with radiation only and
radiation + soy. Lung tissue sections were stained by IHC with the pan-macrophage marker
F4/80. We have previously documented that pneumonitis caused by radiation injury to lung
tissue is associated with thickening of alveolar septa and inflammatory infiltrates (36, 134, 135).
The architecture of the alveolar septa in soy + radiation-treated lungs was thinner akin to control
lung tissue showing decreased pneumonitis compared to radiation–treated lungs (Figure 2.3A),
as previously shown (134, 135). Radiation caused a striking infiltration of F4/80+ macrophages
in lungs that was observed in areas of thickened lung alveolar septa, and was more prominent at
18 weeks after radiation (Figure 2.3A, arrowheads) compared to earlier times points after
radiation (data not shown). Numerous alveolar macrophages were particularly enlarged with
abundant cytoplasm showing the morphology of activated macrophages compared to small
macrophages in control lungs (Figure 2.3A, see arrows and inset). Lungs from mice treated with
radiation + soy had a lower density of F4/80+ macrophages at 18 weeks after radiation compared
to radiation–treated lungs (Figure 2.3A). Moreover, the morphology of the alveolar macrophages
was much smaller than those of radiation-treated lungs (see insets, Figure 2.3A). Quantitation of
F4/80+ cells showed that there was a significant increase in the number of alveolar macrophages
in lungs treated with radiation compared to control lungs (p<0.001, Figure 2.3B). Irradiated mice
supplemented with soy isoflavones showed a significantly reduced number of alveolar
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macrophages compared to radiation alone (p<0.001, Figure 2.3B), to levels similar to those of
control mice. Measurements of the average size of the alveolar macrophages showed that
radiation increased the size of these cells significantly compared to either radiation + soy
(p<0.01, Figure 2.3C) or control (p<0.0001, Figure 2.3C).
To further clarify the functional phenotype of infiltrating macrophages, the NOS2
activation marker for M1 macrophages and Arg-1 activation marker for M2 macrophages were
used to differentiate between pro-inflammatory M1 macrophage phenotype and antiinflammatory M2 macrophage phenotype. Radiation caused a prominent increase in NOS2
staining of lung tissue by 18 weeks after radiation (Figure 2.4A), that was apparent in enlarged
alveolar macrophages (Figure 2.4A, inset). These findings were confirmed by slide scanning
quantitation for the level of staining (Figure 2.4B). In contrast, a lower level of NOS2 staining
was observed following radiation + soy (Figure 2.4A, B). Staining of lungs with Arg-1 showed a
prominent increase in radiation + soy treated lungs compared to radiation alone (Figure 2.4C, D).
In situ staining revealed that radiation caused an increase in a pro-inflammatory M1
macrophage phenotype defined by high NOS2 and low Arg-1 levels at 18 weeks after radiation
(Figure 2.4A, B). This is in contrast to relatively low NOS2 levels and high Arg-1 levels
observed in lungs treated with radiation + soy or in controls (Figure 2.4B, C).
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Figure 2.3. In situ detection of alveolar macrophages in lungs treated with radiation and soy
isoflavones at 18 weeks post-radiation. Lung tissue sections were obtained from control (Con) mice and
mice treated with radiation (Rad) or radiation + soy (Rad+Soy) at 18 weeks after radiation. Sections were
stained by IHC for the marker F4/80 to detect alveolar macrophages in situ in the lungs. Arrows indicate
positive staining of F4/80+ alveolar macrophages. (A). Radiation caused a marked increase in
macrophages in thickened alveolar septa areas (arrowheads). Numerous alveolar macrophages were
particularly enlarged with abundant cytoplasm showing the morphology of activated macrophages
compared to small macrophages in control lungs (see inset). The density of F4/80+ macrophages was
much lower in radiation + soy treated lungs at 18 weeks after radiation compared to radiation–treated
lungs. Alveolar macrophages were smaller, resembling those of control lungs (see inset) and the
architecture of the alveolar septa was thinner akin to control lung tissue showing decreased pneumonitis
compared to radiation–treated lungs. (B). Using ImageJ analysis of IHC slides, the numbers of F4/80 +
alveolar macrophages were counted in 10 fields of 40x per slide and the average number of F4/80+ cells
per field ± SEM is reported for each treatment group. (C). Measurement of the F4/80 + alveolar
macrophage cell areas were performed using ImageJ software in 10 fields of 40x per slide and the average
cell area of macrophages per field ± SEM in each treatment group is reported. The total number of
macrophages counted and measured in 10 fields were 125 for control, 285 for radiation, and 101 for
radiation + soy-treated mice. The means are reported in (B) and (C). All magnifications are at 40x and
insets at 100x to reveal the extent of positive staining and morphology of immune cell subsets. **p<0.01,
***p<0.001, ****p<0.0001, radiation compared to control or radiation + soy compared to radiation alone.
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Figure 2.4. In situ detection of NOS2 and Arg-1 functional macrophage markers in lungs
treated with radiation and soy isoflavones. Lung tissue sections were obtained from control
(Con) mice and mice treated with radiation (Rad) or radiation + soy (Rad+Soy) at 18 weeks after
radiation. Sections were stained by IHC for the markers NOS2 and Arg-1 to determine
macrophage activation status in situ in the lungs. (A). NOS2 staining revealed an abundance of
activated macrophages caused by radiation presenting as clusters of enlarged NOS2+ cells in
areas of pneumonitis (see insets). Lower levels of NOS2+ macrophages were seen in lungs of
mice treated with radiation + soy treated lungs or control which presented as smaller cells (see
inset). (B). Whole slide scanning for quantitation of NOS2 positive staining confirmed these
findings. (C). Compared to radiation, Arg1 expression was greater with radiation + soy. (D).
Whole slide scanning for quantitation of revealed higher levels of Arg-1 in radiation + soy
compared to low levels after radiation alone. For analysis of whole slide scanning, the percentage
of positive area was calculated as the total number of positive pixels divided by total number of
pixels. All magnifications are at 40x and insets at 100x to reveal the extent of positive staining
and morphology of immune cell subsets.
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Radiation-induced infiltration and activation of granulocytes/neutrophils in lung tissue is
decreased by soy isoflavones. Analysis of BAL immune cells showed an increase in neutrophils
by 12 weeks after radiation. In situ detection of granulocyte/neutrophil phenotype and function
were performed by IHC staining of lung tissue sections for Gr-1 (Ly6C/Ly6G) and the neutrophil
marker NIMP at 12 weeks after radiation. Radiation caused a pronounced increase in clusters of
Gr-1+ granulocytes in areas of thickened septa at 12 weeks after radiation (Figure 2.5, see inset).
In contrast, following radiation + soy the alveolar septa were not as thickened and contained
much lower levels of Gr-1+ cells (Figure 2.5). NIMP staining for neutrophils followed the same
patterns with increased neutrophil infiltrates induced by radiation and decreased by radiation +
soy (Figure 2.5).
Concurrent with increased infiltration of Gr-1+ and NIMP+ cells, lungs treated with
radiation also showed multiple cells with intense MPO staining (Figure 2.6). MPO+ cells formed
clusters in areas of thickened alveolar septa, which are indicative of a massive infiltration of
activated neutrophils, as confirmed by quantitative analysis of the level of positive staining
(Figure 2.6A, B). However, MPO+ infiltrates were greatly reduced in lungs treated with radiation
+ soy (Figure 2.6A, B). These data indicate that radiation-induced neutrophil activation in lung
tissue is inhibited by soy isoflavones. These findings were confirmed by western blot analysis of
MPO expression in lung tissue lysates showing an increase induced by radiation, which was
inhibited by the addition of soy isoflavones (Figure 2.6C).
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Figure 2.5. Effect of soy isoflavones on radiation-induced infiltration of
granulocytes/neutrophils in lung tissue. Lungs tissue sections were obtained from control
(Con) mice and mice treated with radiation (Rad) or radiation + soy (Rad+Soy) at 12 weeks after
radiation. Sections were stained by IHC for Gr-1 (Ly6C/Ly6G) and NIMP to detect
granulocytes/neutrophils. Staining of Gr-1+ granulocytes showed that radiation caused a
pronounced increase in clusters of granulocytes in areas of thickened septa at 12 weeks after
radiation (see inset). In contrast, following radiation + soy treatment the alveolar septa were not
as thickened and much lower levels of positive cells for Gr-1 were observed. All magnifications
are at 40x and insets at 100x to reveal the extent of positive staining and morphology of immune
cell subsets.

48

Figure 2.6. Inhibition of radiation-induced activation of neutrophils in lung tissue. Lungs
tissue sections were obtained from control (Con) mice and mice treated with radiation (Rad) or
radiation + soy (Rad+Soy) at 12 weeks after radiation. (A, B). Sections were stained by IHC for
the neutrophil activation marker myeloperoxidase (MPO). Radiation caused extensive MPO
staining in the lung tissue that is indicative of activated neutrophil infiltration. MPO+ activated
neutrophils were present in clusters in areas of thickened alveolar septa (see inset) at 12 weeks
after radiation. The levels of MPO were greatly reduced in radiation + soy treated lungs.
(B). Whole slide scanning for quantitation of MPO positive staining confirmed these findings.
For analysis of whole slide scanning, the percentage of positive area was calculated as the total
number of positive pixels divided by total number of pixels. NIMP+ neutrophils were also
increased in lung tissue by radiation, but not by radiation + soy. All magnifications are at 40x
and insets at 100x to reveal the extent of positive staining and morphology of immune cell
subsets. (C). Western blot analysis of MPO on whole tissue lysates obtained from lungs showed
an increase induced by radiation, which was inhibited by the addition of soy isoflavones. Band
intensities were quantified using ImageJ (NIH) densitometry analysis.
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DISCUSSION

Soy isoflavones can reduce the extent of inflammatory infiltrates and vascular damage
caused by radiation in the lungs (36, 134, 135), suggesting that soy modulates immune responses
triggered by injury. Studies on the effect of soy and the immune system in other diseases besides
cancer also support this hypothesis. A recent study suggested that genistein may down-regulate
cytokine-induced pro-inflammatory pathways in human brain microvascular endothelial cells
(106). Soy isoflavones have been shown in vitro to have anti-inflammatory mechanisms via
modulation of leukocyte-endothelial cell interactions (107). The goals of our current study were
to determine whether soy isoflavones modulate innate immune cells putatively involved in
radiation-induced inflammation in normal lungs by examining the bronchoalveolar space and
lung parenchyma compartments.
Macrophages are recruited as a first response to radiation-induced damage in the tumor
microenvironment in irradiated tissues (143, 151). Alterations in lung macrophages after
radiation have been observed during early and late phases of tissue injury (152, 153) supporting
the idea that macrophage activation contributes, at least partially, to the pathogenesis of
radiation-induced lung injury. Therefore, modulation of the response of macrophages to radiation
could be a mechanism of radioprotection by soy isoflavones. By 2-4 months after radiation, an
increase in the number and size of macrophages was observed both in the bronchoalveolar space
and lung parenchyma compartments, indicative of macrophage activation, confirming previous
reports (152, 153). Soy isoflavones durably decreased the frequency and size of macrophages
found in the lung after radiation.

50

Our flow cytometry analysis of lung parenchyma after lavage identified subsets of
residual F4/80+CD11c+ alveolar macrophages and F4/80+CD11c- interstitial macrophages, as
previously described by others (154). A decrease in interstitial macrophages was induced by
radiation, whereas this cell subset was protected by the addition of soy isoflavones to radiation
treatment. Interstitial macrophages have been shown to have more immunoregulatory roles in the
maintenance of lung homeostasis and in pathologic conditions (38). Soy could potentially inhibit
inflammatory responses by protecting interstitial macrophages. In contrast, alveolar macrophages
exhibit a greater capacity to functionally contribute to pulmonary inflammation and antimicrobial defense (37). In our present study, soy isoflavones inhibited alveolar macrophage
infiltration and activation induced by radiation, a mechanism that could play a role in controlling
inflammatory processes. These findings suggest that soy modulation of macrophage subset
functions in response to radiation may play a critical role in soy-mediated radioprotective effects
in lungs. We have further studies ongoing to clarify the role of interstitial and alveolar
macrophages in radiation-induced lung inflammation and their regulation by soy isoflavones.
In radiation-treated lungs, our analysis of myeloid cells in situ by IHC showed extensive
infiltration of inflammatory cells at sites of pneumonitis, consisting of macrophages and
neutrophils in the lungs. Both types of immune cells were morphologically and molecularly in a
status of activation. In contrast, soy supplementation to radiation decreased both the infiltration
and activation of myeloid cells. The influence of soy isoflavones on M1 and M2 macrophage
polarization in irradiated lungs could be a mechanism of radioprotection. Macrophages possess
the plasticity to respond to environmental stressors in tissues that functionally range from M1
pro-inflammatory to M2 immunosuppressive, anti-inflammatory phenotypes (41, 155). These
two phenotypes can be distinguished by expression of NOS2 and Arg-1 (156). Normal tissue
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exposed to ionizing radiation generates “damage” signals and type 1 cytokines, such as IL-1β,
IL-6, and TNF-α, that classically activate macrophages (M1) and drive the acute/chronic
pulmonary inflammation induced by radiation (157, 158). M1 macrophages produce NOS2,
which generates reactive NO species, thus promoting inflammation. Alternatively activated
macrophages (M2) can be generated by type 2 cytokines, such as IL-4, IL-10, and TGF-β, and
are important for the resolution of inflammation (155, 159, 160). M2 macrophages produce Arg1, which generates L-orthonine, a precursor of proline, from arginine (41). Proline enhances
collagen synthesis, thus promoting tissue repair and resolution of inflammation (42). Our studies
now demonstrate that radiation induced a pro-inflammatory M1 phenotype in lungs at late time
points, while mice receiving soy isoflavones and radiation switched to an anti-inflammatory M2
subtype with increased levels of Arg-1 and decreased NOS2. These data indicate that soy
isoflavones supplementation to radiation could result in skewing of alveolar macrophages from a
pro-inflammatory M1 phenotype toward an anti-inflammatory M2 phenotype, which has been
found to mediate the resolution of inflammation, including healing and decreased fibrosis. These
data are in agreement with our previous findings demonstrating that soy isoflavones inhibited the
release of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and IFN-γ which are
induced by radiation in lung tissues and promote an M1 macrophage phenotype (134).
Infiltration and activation of neutrophils into the lung are key factors that occur after
damage to lung tissue (44, 152). Therefore, inhibition of the inflammatory neutrophil response
induced by radiation in the pulmonary environment may result in reduced host tissue damage.
Our flow cytometry studies of lung single cell suspensions showed that CD11b+Ly6G+
neutrophils were increased after radiation. Immunostaining of lung tissue sections confirmed
clusters of neutrophils in sites of pneumonitis caused by radiation. These neutrophils were
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activated, as confirmed by MPO staining. Treatment with soy isoflavones inhibited radiationinduced neutrophil infiltration and activation, suggesting a mechanism of protection from tissue
damage by soy.
In summary, our pre-clinical study in lung suggests that a radioprotective mechanism of
soy isoflavones could involve inhibition of infiltration and activation of macrophages and
neutrophils in irradiated lungs. Furthermore, soy caused a polarization from M1 to M2
macrophage that could play a role in the resolution of radiation-induced acute/chronic
inflammation in the lungs. It was interesting to note that soy had a protective effect on regulatory
interstitial macrophages that could participate in maintaining lung homeostasis and control
inflammation and tissue damage.
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CHAPTER 3
Soy Isoflavones Mediate Radioprotection of Normal Lung Tissue by Promoting CD11b+
Granulocyte-Associated Arginase-1

ABSTRACT

Radiation therapy for lung cancer causes normal tissue injury, including pneumonitis and
fibrosis. We have shown that treatment with soy isoflavones mitigates radiation-induced lung
injury, but the cellular and molecular mediators of radioprotection remain unclear. We
hypothesize that soy isoflavones reduce radiation injury by promoting an anti-inflammatory
phenotype in myeloid cells early in irradiated lung tissue. This chapter investigates the role of
arginase-1 (Arg-1) associated with CD11b+ granulocytes that could act as an immunosuppressive
molecule involved in soy-mediated radioprotection of lung tissue. BALB/c mice received a
single 10 Gy dose of thoracic irradiation with a mixture of soy isoflavones (83% genistein, 15%
daidzein, 0.3% glycitein) given orally at 1 mg/day continuously. Lungs were harvested at 1 week
post-radiation and Arg-1 was detected by Western blot and immunohistochemistry. The
phenotype of lung myeloid cells associated with intracellular Arg-1 expression was analyzed by
flow cytometry. Subsequent IL-1β, IL-6, and TNF-α production in lungs was measured at 4
weeks post-radiation by ELISA as readout for immunosuppression. At 1 week after radiation,
both Western blot and immunohistochemistry showed that while Arg-1 levels in lung tissue are
decreased by radiation, the level is maintained in radiation + soy treated lungs. Radiation and/or
soy do not affect the percentage of lung CD11b+ myeloid cells. However, radiation decreases the
percentage of CD11b+Arg-1+ cells in lungs (p=0.0028), whereas soy isoflavones combined with
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radiation caused an increase in CD11b+Arg-1+ cell subset (p=0.0096). Radiation decreases the
percentage of granulocytes expressing CD11b+Ly6C-Ly6G+Arg-1+ (p=0.0050), while these Arg1+ granulocytes were not reduced in radiation + soy treated lungs (p=0.0032). At 4 weeks, soy
inhibited increases in IL-1β, IL-6, and TNF-α pro-inflammatory cytokines induced by radiation
in the lung. Radioprotection by soy isoflavones involves an early process of immunosuppressive
events that subsequently causes a decrease downstream inflammatory cytokine expression and
tissue damage by promoting Arg-1+ granulocytes in lungs.
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INTRODUCTION

Radiation pneumonitis is caused by an early inflammatory process triggered by lung
tissue damage. This process occurs immediately after radiation and induces the expression and
release of pro-inflammatory cytokines and chemokines which drive the recruitment of
inflammatory cells into the injured tissue (29, 30, 141). Infiltrating inflammatory cells are
stimulated and activated, producing additional mediators, resulting in a cytokine cascade (31,
32). The expansion and perpetual activation of inflammatory cells, as well as lung parenchyma,
leads to clinical pneumonitis.
Inflammation is causally linked to radiation pneumonitis severity and outcome. In
Chapter 2, our findings suggest that one radioprotective mechanism of soy isoflavones involves
the inhibition of infiltration and activation of macrophages and neutrophils in irradiated lungs.
On the other side of the pro/anti-inflammatory radioprotection axis, soy isoflavones may
promote immunosuppressive phenotypes and anti-inflammatory molecular mediators after
injury. Thus one possible mechanism of radioprotection in lung tissue could be achieved by the
indirect suppression of radiation-induced pro-inflammatory cells and pathways. In Chapter 3, we
investigate the role of myeloid-derived suppressor cells (MDSCs) and their expression of
arginase-1 in the mitigation of radiation-pro-inflammatory cytokines by soy isoflavones in lung
tissue to understand the role of immunosuppressive subsets and mediators in radioprotection of
lung tissue by soy isoflavones.
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MATERIALS AND METHODS

Mice
Female BALB/c mice (Harlan, Indianapolis, IN) 5-6 weeks old, were housed and handled
in animal facilities accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care. The animal protocol was approved by Wayne State University
Institutional Animal Care and Use Committee.

Soy isoflavones
The soy isoflavone mixture G-4660 used is a pure extract of 98.16% isoflavones from
soybeans consisting of 83.3% genistein, 14.6% daidzein and 0.26% glycitein (manufactured by
Organic Technologies and obtained from the National Institutes of Health [NIH], Bethesda,
MD). The soy isoflavone mixture was dissolved in DMSO and mixed with sesame seed oil at a
1:20 ratio just prior to treatment to facilitate gavage and avoid irritation of the esophagus by
DMSO (36, 134, 135).

Lung irradiation
Radiation was delivered to the thoracic cage comprising the whole lung. Three
anesthetized mice, in jigs, were positioned under a 6.4 mm lead shield with 3 cut-outs in an
aluminum frame mounted on the X-ray machine to permit selective irradiation of the lung in 3
mice at a time, as previously described (134). The radiation dose to the lung and the scattered
dose to areas of the mouse outside of the radiation field were carefully monitored. To minimize
backscattering of radiation, the bottom of the aluminum frame that holds the jigs was hollowed
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out and the backplate of the jig was thinned to 1.6mm thickness. Under these conditions and the
lead shielding, the X ray dose to the shielded regions was reduced to 1% of the dose to the
irradiated field. The dose rate was 101 cGy/min and half value layer was 2 mm Cu. Photon
irradiation was performed at a dose of 10 Gy with a Siemens Stabilipan X-ray set (Siemens
Medical Systems, Inc., Erlangen, Germany) operated at 250 kV, 15 mA with 1 mm copper
filtration at a distance of 47.5 cm from the target.

Experimental design
Mice were pre-treated with oral soy isoflavones each day for 3 days at a dose of 5mg/day
(equivalent to 250mg/kg). Then, the lung was selectively irradiated with 10 Gy. Soy treatment
was continued on a daily basis for 5 more days at 5mg/day. Then mice were treated with a lower
soy dose of 1mg/day (equivalent to 50mg/kg), given daily 5 days a week for up to 4 weeks. The
rationale for giving a higher dose of soy isoflavones for pre-treatment and just after radiation is
to optimize the effect of soy, based on previous studies (36, 140). At different time points,
separate mice from each treatment group were either processed for flow cytometry studies or
homogenized for ELISA, snap frozen for western blot, or mice were used to fix lungs in situ with
formalin for histology studies as detailed below.

Analysis of MDSC subsets and intracellular Arg-1 by flow cytometry on single-cell
suspensions of lungs
Following a BAL wash, lungs were excised, minced, and digested with 0.4 mg/mL
collagenase IV for 45 minutes at 37° C. Digested lungs were passed through a wire mesh, then a
0.7 μm nylon mesh. Red blood cells were removed by incubating in red blood cell lysis buffer
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for 2 minutes at room temperature. Single-cell suspensions obtained from the lungs were
incubated with Fc receptor-blocking antibody (eBioscience, San Diego, CA) prior to staining to
reduce non-specific binding. To determine the phenotype of immune cells, cells were
immunostained using a 4-color fluorophore combination of antibodies consisting of CD45-APC,
CD11b-PE, Ly6C-PE-Cy7, Ly6G-PE-Cy5.5 (eBioscience). Cells were fixed with 4%
paraformaldehyde in PBS and incubated with intracellular Arg-1 purified antibody (1:50, BD
Biosceinces, San Jose, CA). Cells were washed in 1X Permeabilization Buffer (eBioscience) and
incubated with and additional fluorescent rat anti-mouse IgG1-FITC secondary antibody (BD
Pharmingen). Fixable viability dye eFluor 450 (eBioscience) was used to exclude dead cells from
analysis. Cells were analyzed by flow cytometry using a BD LSR II flow cytometer (BD
Biosciences, San Jose, CA) in the Microscopy, Imaging and Cytometry Resources Core at
Wayne State University School of Medicine, followed by analysis on FlowJo v10 software (Tree
Star Inc., Ashland, OR).

Preparation of lung tissue protein lysates and western blot analysis
Mice were sacrificed at 1 week post-irradiation. Lungs were resected and snap frozen. To
prepare lung tissue protein lysates, frozen lungs were thawed, weighed, and homogenized in 10%
w/v of lysis buffer using a gentleMACS tissue dissociator (Miltenyi Biotec, Bergisch, Germany).
The suspension was centrifuged at 4000 x g for 5 minutes at 4°C and the protein extracts were
frozen at -80°C until analysis. For western blot analysis, total lung protein extracts (90 µg) were
loaded and separated on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDSPAGE) and transferred to Whatman membranes (GE Healthcare Life Sciences, Pittsburgh, PA).
Membranes were incubated with anti-arginase-1 (Arg-1) antibody (eBioscience, San Diego, CA;
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1:200) overnight at 4°C. Membranes were washed and incubated with horseradish peroxidaseconjugated secondary antibody (Vector Labs, 1:2000) at room temperature for 1 hour.
Immunoreactive protein bands were visualized by SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific, Waltham, MA) and captured on a digital imaging system
(Fotodyne Inc., Hartland, WI). Membranes were re-probed with anti-β-actin Ab as a loading
control (137).

Immunohistochemistry (IHC)
Mice were sacrificed at 1 week post-irradiation and lungs were intratracheally instilled
with 10% buffered formalin and resected, embedded in paraffin, and sectioned. Sections were
blocked with IHC Tek Antibody Diluent (IHC World, Woodstock, MD) then incubated with
primary purified monoclonal antibodies directed against arginase-1 (Arg-1) (eBioscience, San
Diego, CA) overnight at 4° C. Lung sections were then incubated with biotinylated secondary
antibodies (Vector Labs, Burlingame, CA) at 1:300 for 1 hour at room temperature. Staining was
amplified with the avidin-biotin system Vectastain ABC Reagent Kit (Vector Labs) and
visualized with the Vector DAB Substrate Kit for peroxidase (Vector Labs). Sections were
counterstained with IHC-Tek Mayer’s Hematoxylin (IHC World, Woodstock, MD) and mounted
with Permount mounting media (Electron Microscopy Sciences, Hatfield, PA). Arg-1 expression
in lung tissue after radiation was evaluated on a Nikon E800 microscope (Nikon Inc., Melville,
NY).

Enzyme-linked immunosorbant assay (ELISA)
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Mice were sacrificed at 4 weeks post-irradiation. Lungs were resected and snap frozen.
To prepare lung homogenates, frozen lungs were thawed, weighed, and homogenized in 10%
w/v of phosphate buffered saline (PBS) with Complete Protease Inhibitor Cocktail Tablets
(Roche Diagnostics, Indianapolis, IN) using a gentleMACS tissue dissociator (Miltenyi Biotec,
San Diego, CA). The suspension was centrifuged at 4000 x g for 5 minutes at 4°C and the
supernatant was frozen at -80°C. Lung homogenates were assayed for IL-1β, IL-6, and TNF-α,
using the respective Ready-SET-GO ELISA kits (eBioscience, San Diego, CA) according to
manufacturer’s instructions.

Statistical analysis
Data are expressed as mean ± SEM. Comparisons between means of two treatment groups
were analyzed by two-tailed unpaired Student’s t test using GraphPad Prism version 6.0 software
(GraphPad Software Inc., San Diego, CA). A value of p<0.05 was considered statistically
significant.
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RESULTS

Effect of radiation and soy isoflavones on Arg-1 levels in lung tissue. Lungs tissue sections
were obtained from control mice and mice treated with radiation or radiation + soy at 1 week
post-irradiation and stained by IHC for Arg-1 to detect expression in situ. In control lungs, Arg1+ cells are evenly distributed across alveolar septa (Figure 3.1A). However, Arg-1+ cells were
sparsely found in areas of thickened septa and staining was overall greatly reduced in lungs
treated with radiation (Figure 3.1A). Staining of lungs from mice receiving soy isoflavones in
conjunction with radiation revealed a degree of Arg-1 positivity that was similar to control lungs
(Figure 3.1A). These data indicate that radiation caused the depletion of Arg-1+ cells normally
occurring the lung, or reduced the expression of Arg-1 in cells in the lung tissue, while soy
isoflavones protected from this radiation effect. These findings were confirmed by western blot
analysis of Arg-1 expression in lung tissue lysates showing a decrease induced by radiation,
which was inhibited by the addition of soy isoflavones (Figure 3.1B, C).
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Figure 3.1. In situ detection of Arg-1 in lung tissue treated with radiation and soy
isoflavones at 1 week post-irradiation. Lungs tissue sections were obtained from control (Con)
mice and mice treated with radiation (Rad) or radiation + soy (Rad+Soy) at 1 week after
radiation. (A). Sections were stained by IHC for Arg-1 to detect expression in situ. Staining of
Arg-1+ cells showed that radiation caused a pronounced decrease in these cells in areas of
thickened septa at 1 week after radiation. In contrast, following radiation + soy treatment, higher
levels of positive cells for Arg-1 were observed and were comparable to levels in control mice.
Secondary antibody alone is shown as a staining control. All magnifications are at 40x. (B).
Western blot analysis of Arg-1 on whole tissue lysates obtained from lungs showed an increase
induced by radiation, which was inhibited by the addition of soy isoflavones. (C). Band
intensities were quantified using ImageJ (NIH) densitometry analysis. Radiation + Soy (R+S).
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Effect of radiation and soy isoflavones on Arg-1 expression in CD11b+ myeloid cell
compartment in lung tissue. We examined myeloid cells in the lung to determine if this
arginase-expressing population was being altered by radiation or soy isoflavones treatment. Lung
cell suspensions were immunostained using antibodies directed against CD45 and CD11b, as
well as intracellular Arg-1 from lungs treated with soy, radiation or radiation + soy at 1 week
after radiation, as detailed in Materials and Methods. Intracellular Arg-1 expression in CD11b+
myeloid cells in the lung was evaluated (Figure 3.2).
Radiation and/or soy isoflavones treatment did not affect the percentage of CD11b+ cells
in the lung at 1 week post-radiation (Figure 3.3A). However, radiation significantly decreased
the percentage of Arg-1+ cells within the CD11b+ cellular compartment in lungs (p=0.0228)
compared to control

(Figure 3.3B), while lungs from Rad+Soy mice show significantly

increased percentages of CD11b+Arg-1+ cells (p=0.0096) compared to radiation alone (Figure
3.3B).
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Figure 3.2. Gating strategy for the detection of intracellular Arg-1 in CD11b+lung
leukocytes. Single-cell suspensions obtained from the lungs were analyzed. Fixable viability dye
eFluor 450 was used to exclude dead cells from analysis and gate on live cells. Side scatter are
(SSC-A) and side scatter width (SSC-W) were used to identify single cell events (singlets).
CD45+ lung leukocytes were gated on, followed by gating on CD11b+ cells within this leukocyte
gate. Intracellular Arg-1 cells were gated on within the CD11b+ lung leukocytes.
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Figure 3.3. Effect of soy isoflavones on intracellular Arg-1 levels in CD11b+ leukocytes in
lung at 1 week post-radiation. (A). Analysis of CD45+CD11b+ leukocytes in lung. At 1 week
after radiation, lungs from control (Con) mice, and mice treated with soy (Soy), radiation (Rad)
or radiation + soy (R+S) were dissociated into single cell suspensions. Cells were stained with
anti-CD45, anti-CD11b, anti-Ly6C, and anti-Ly6G fluorescent antibodies to analyze CD11b+
myeloid cells within CD45+ leukocyte populations by flow cytometry. Percentages of CD11b+
cells within CD45+ cells are shown for lungs from control and treated mice. The data are
presented as mean ± SEM (n = 3 mice/group). (B). Intracellular Arg-1 expression in CD11b+
lung leukocytes. After cell surface staining, cells were stained with anti-Arg-1 purified antibody
followed by fluorescent anti-IgG-FITC to analyze intracellular Arg-1 in CD11b+ cells by flow
cytometry. Percentages of CD11b+Arg-1+ cells within CD45+ leukocytes are shown for lungs
from control and treated mice. The data are presented as mean ± SEM (n = 3 mice/group).
*p<0.05, **p<0.01 radiation compared to control or radiation + soy compared to radiation alone.
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Flow cytometry analysis of intracellular Arg-1 in CD11b+ myeloid-derived supporessor cell
subsets in lung tissue treated with radiation and soy isoflavones. To further interrogate the
specific CD11b+ cell populations that are augmented by radiation and soy isoflavones treatment,
we examined intracellular expression of Arg-1 in monocytic- and granulocytic-MDSC subsets by
flow cytometry (Figure 3.4). Lung cell suspensions were immunostained using a 5-color
fluorophore combination of antibodies directed against CD45, CD11b, Ly6C, Ly6G and
intracellular Arg-1 from lungs treated with soy isoflavones, radiation or radiation + soy at 1 week
after radiation, as detailed in Materials and Methods. CD11b+ myeloid subsets were gated based
on their differential expression of Ly6C and Ly6G to analyze monocytic-MDSCs
(CD11b+Ly6C+Ly6G-) and granulocytic-MDSCs (CD11b+Ly6C-Ly6G+) (Figure 3.4).
In order to dissect the specific CD11b+ cells population responsible for Arg-1 expression
in the lung, we analyzed Ly6C and Ly6G subsets (Figure 3.5A). CD11b+Ly6C-Ly6G+
granulocytic-MDSCs highly express Arg-1 (~70% in control mice), while other CD11b+ Ly6C
and Ly6G subpopulations minimally expressed Arg-1. Only about 1% of monocytic-MDSCs
expressed Arg-1 across all treatment groups (data not shown). Radiation and/or soy isoflavones
treatment did not affect the percentage of CD11b+Ly6C-Ly6G+ granulocytic-MDSC in the lung
at 1 week post-radiation (Figure 3.5B). However, radiation significantly decreased the
percentage of CD11b+Ly6C-Ly6G+Arg-1+ granulocytes in lungs (p=0.0050) compared to control
(Figure 3.5C), while CD11b+Ly6C-Ly6G+ granulocytes from Rad+Soy mice had significantly
more Arg-1+ cells (p=0.0032), compared to radiation alone, and these percentages were
comparable to those of control lungs (Figure 3.5C).
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Figure 3.4. Gating strategy for granulocytic and monocytic MDSC subsets in the lungs.
Single-cell suspensions obtained from the lungs were analyzed. CD11b+ cells within CD45+
leukocytes were gated (see Figure 3.2 for gating method). To further interrogate the specific
CD11b+ cell populations that are being augmented by radiation and soy isoflavones treatment,
we examined in monocytic- and granulocytic-MDSC subsets by flow cytometry. CD11b+
myeloid subsets were gated based on differential expression of Ly6C and Ly6G to analyze
monocytic-MDSCs (CD11b+Ly6C+Ly6G-) and granulocytic-MDSCs (CD11b+Ly6C-Ly6G+).
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Figure 3.5. Intracellular flow cytometry analysis of Arg-1 expression in CD11b+Ly6CLy6G+ granulocytic-MDSCs at 1 week after radiation. (A). Analysis of CD11b+Ly6C-Ly6G+
granulocytic MDSCs in lung. At 1 week after radiation, lungs from control (Con) mice, and mice
treated with soy (Soy), radiation (Rad) or radiation + soy (R+S) were dissociated into single cell
suspensions. Cells were stained with anti-CD45, anti-CD11b, anti-Ly6C, and anti-Ly6G
fluorescent antibodies to analyze CD11b+ myeloid cells within CD45+ leukocyte populations by
flow cytometry. (B) Percentages of CD11b+Ly6C-Ly6G+ granulocytic MDSCs within the
CD11b+ gated cells are shown for lungs from control and treated mice. The data are presented as
mean ± SEM (n = 3 mice/group). (C). Intracellular Arg-1 expression in CD11b+ lung leukocytes.
After cell surface staining, cells were stained with anti-Arg-1 purified antibody followed by
fluorescent anti-IgG-FITC to analyze intracellular Arg-1 in CD11b+ cells by flow cytometry.
Percentages of CD11b+Arg-1+ cells within CD45+ leukocytes are shown for lungs from control
and treated mice. The data are presented as mean ± SEM (n = 3 mice/group). **p<0.01 radiation
compared to control or radiation + soy compared to radiation alone.
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Effect of soy-mediated early immunosuppressive phenotype in irradiated tissue on
subsequent radiation-induced pro-inflammatory cytokine levels in lung homogenates. We
showed that soy isoflavones promote an immunosuppressive granulocytic-MDSC phenotype at
an early time point after radiation, with increased CD11b+Ly6C-Ly6G+Arg-1+ cells in irradiated
lungs with in mice receiving soy isoflavones treatment. To determine if early Arg-1 expression
in granulocytic-MDSCs results in a later functional anti-inflammatory effect, we measured
radiation-induced pro-inflammatory cytokine expression subsequent to the soy-mediated
promotion of immunosuppressive MDSC phenotype observed at 1 week. Indeed, soy isoflavones
treatment inhibited radiation-induced cytokine production in lung tissue at 4 weeks postirradiation (Figure 3.6). Inflammatory cytokines associated with radiation injury were
significantly reduced by soy isoflavones supplementation, including IL-1β (p=0.0030), IL-6
(p=0.0061), and TNF-α (p=.0057). Increased Arg-1 expression at an earlier time point (1wk
post-radiation) may contribute to the attenuation of pro-inflammatory cytokine expression
observed in lungs at a later time point (4wks post-radiation).
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Figure 3.6. Supplementation with soy isoflavones inhibits radiation-induced cytokine
production in lung tissue at 4 weeks post-radiation. Cytokine levels were measured by ELISA
in lung homogenates obtained from mice at a time point of 4 weeks following irradiation. The
data are presented as mean ± SEM (n = 4-9 mice/group). **p<0.01 radiation compared to control
or radiation + soy compared to radiation alone.
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DISCUSSION

Radiation-induced pro-inflammatory cytokine expression in the lung plays an important
role in promoting and perpetuating inflammation that contributes to the pathology of lung injury
after thoracic radiation. Acute inflammation triggered after a single dose of radiation sets off a
cascade of events that is akin to an aberrant wound healing response. We have reported in
preclinical mouse models that supplementation with soy isoflavones to thoracic irradiation
mitigates radiation-induced inflammatory cytokines, infiltration of inflammatory cells and
fibrosis (36, 134, 135), but the immunosuppressive mediators of radioprotection remain unclear.
In Chapter 2, we investigated the role of macrophages and neutrophils in the mitigation of
radiation-induced inflammatory events by soy isoflavones in lung tissue. Our findings suggested
that a radioprotective mechanism of soy isoflavones in lung involves the inhibition of infiltration
and activation of macrophages and neutrophils in irradiated lungs.
Additionally, soy isoflavones may also radioprotect
by promoting immunosuppressive phenotypes and anti-inflammatory molecular
mediators after injury. Thus, radioprotection in lung tissue could also be achieved by the indirect
suppression of radiation-induced pro-inflammatory cells and pathways. In this chapter, we
demonstrated that soy isoflavones play a role in the promotion of an immunosuppressive
phenotype in the lung at an early time point after a single dose of irradiation, and may
downregulate damaging radiation-induced inflammation.
We found that arginase-1, an enzyme with an important immunosuppressive and
regulatory role (42), was decreased in lungs at 1 week post-irradiation, as confirmed by IHC and
western blot. Soy isoflavones supplementation protected Arg-1 levels in irradiated lungs, similar
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to that of control lungs. In control lungs, Arg-1+ cells are evenly distributed across alveolar septa
while Arg-1+ cells were sparsely found in areas of thickened septa and staining was overall
greatly reduced in lungs treated with radiation. Staining of lungs from mice receiving soy
isoflavones in conjunction with radiation revealed a degree of Arg-1 positivity that was similar to
control lungs. These data indicate that radiation caused the depletion of Arg-1+ cells that
normally occur the lung, or reduced the expression of Arg-1 in cells lung tissue, while soy
isoflavones protected from this radiation effect. These findings were confirmed by western blot
analysis of Arg-1 expression in lung tissue lysates showing a decrease induced by radiation,
which was inhibited by the addition of soy isoflavones. Decreased Arg-1 levels in the lung after
radiation may allow for tissue damaging pro-inflammatory processes to proceed unhindered, and
our data indicate that soy isoflavones may mediate radioprotection by promoting
immunosuppression via Arg-1.
To identify the specific Arg-1+ cell population affected by radiation and soy isoflavones,
we performed flow cytometry studies to probe the myeloid compartment of the lungs, as these
cells are known to produce arginase (161). Radiation and/or soy isoflavones treatment did not
affect the percentage of CD11b+ cells in the lung at 1 week post-radiation, however radiation
significantly decreased the percentage of Arg-1+ cells within the CD11b+ cellular compartment
in lungs compared to control. A subset of CD11b+ cells showed typical characteristics of
myeloid-derived suppressor cells, with a CD11b+Ly6C-Ly6G+ immunophenotype and high
arginase-1 expression (155). This population of CD11b+Ly6C-Ly6G+ MDSCs are granulocytic in
nature, given their high expression of Ly6G and lack of Ly6C. At 1 week post-radiation, we
found that these granulocytic-MDSCs in irradiated lungs showed significantly less intracellular
Arg-1 compared to control, while lungs from Rad+Soy mice revealed significantly increased
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percentages of CD11b+Ly6C-Ly6G+Arg-1+ cells compared to radiation alone. These finding
suggest that soy isoflavones supplementation in mice receiving a single dose of thoracic
radiation promotes Arg-1 expression in a granulocytic subset of MDSCs in the lung at an early
point after irradiation.
In order to determine if this early promotion of Arg-1 in granulocytic MDSCs mediated
by soy isoflavones results in downstream immunosuppression at a later time point, we measured
the effect of soy isoflavones treatment on pro-inflammatory cytokines levels in lung
homogenates at 4 weeks post-radiation. Inflammatory cytokines are implicated in radiationinduced pneumonitis and fibrosis (30, 162). We found that soy isoflavones significantly reduced
the levels of the radiation-induced pro-inflammatory cytokines IL-1β, IL-6, and TNF-α at 4 week
post-radiation. These studies indicate that the early promotion of Arg-1+ granulocytic-MDSCs by
soy isoflavones in irradiated lung may result in the later inhibition of radiation-induced
inflammatory cytokine release.
Arg-1 was shown to attenuate inflammatory cytokine expression in a rabbit model of
atherosclerosis (163). Wang et. al. reported that upregulation of Arg-1 resulted in significantly
decreased macrophage infiltration and inflammation in atherosclerotic plaques, corroborating our
findings of soy radioprotection in lungs. In summary, our pre-clinical study in lung suggests that
a radioprotective mechanism of soy isoflavones could involve the promotion of granulocytic
myeloid-derived suppressor cells that express Arg-1 after radiation, resulting in subsequent
downregulation of tissue damaging inflammation.
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CHAPTER 4
Molecular Mediators of Radioprotection of Lung Tissue by Soy Isoflavones

ABSTRACT

Radiation-induced lung injury results from a cascade of inflammatory processes leading
to clinical pneumonitis and fibrosis. Our lab has previously reported that treatment with soy
isoflavones mitigates inflammation and fibrosis but the mechanism of radioprotection was
unclear. In this final chapter, we investigate molecular mediators of radiation-induced
inflammation modulated by soy isoflavones that protect lung tissue from injury in naïve mice.
BALB/c mice received a single 10 Gy thoracic irradiation with soy isoflavones given orally at 1
mg/day, prior-to and continuously after radiation. Lungs were resected at different time points up
to 18 weeks after radiation and processed for histology, western blot, and ELISA. E-cadherin, a
cell adhesion molecule important airway epithelium barrier function, was assessed by IHC. Lung
homogenates were processed to determine cytokine expression by ELISA and expression of NFκB p65 by western blot. At 4 weeks post-irradiation, E-cadherin positive staining was decreased
in areas of thickened septa while considerably higher levels of E-cadherin were observed
following radiation + soy treatment, compared to radiation-treated lungs. Soy isoflavones
modulated radiation-induced Th1/M1 pro-inflammatory cytokines more so than Th2/M2
cytokines. NF-κB p65 transcription factor subunit that plays a role in promoting inflammation
was upregulated by radiation and decreased in lungs from mice treated with radiation and soy.
These findings suggest that a mechanism of radioprotection by soy isoflavones involves the
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regulation of radiation-induced molecular inflammatory events caused by the destruction of
normal lung tissue.
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INTRODUCTION

Radiation-induced pneumonitis and fibrosis is initiated by an inflammatory response
triggered by tissue and cell damage that results in the cyclical induction of pro-inflammatory
cytokines and chemokines which recruit inflammatory immune cells in the lung tissue and drive
RILI pathogenesis (23, 29, 30). In a pre-clinical lung cancer model, we showed that
supplementation with a mixture of soy isoflavones given pre- and post-thoracic irradiation
mitigated the vascular damage, inflammation and fibrosis caused by high dose radiation injury to
lung tissue, suggesting that soy can alter the radiation-induced inflammatory response (36, 134).
In chapters 2 and 3 of this dissertation, we demonstrate that soy isoflavones inhibit radiationinduced

macrophage

and

neutrophil

infiltration

and

activation,

while

promoting

immunosuppressive function of granulocytic MDSCs that are depleted in irradiated lungs. This
chapter investigates the molecular mediators of inflammation modulated by soy isoflavones that
protect lung tissue from radiation-induced injury in naïve mice.
Thoracic radiation therapy can damage the lung epithelial barrier integrity by interrupting
adherens junctions that bind cells together within this organ. E-cadherin is a cell-cell adhesion
molecule critical for the maintenance of tight junctions between cells of the airway epithelium
(48). Decreased E-cadherin expression in the lung would be indicative of a disrupted epithelial
barrier, which can result in the recruitment of inflammatory cellular and molecular mediators and
drive chronic inflammation. Thus, the effect of soy isoflavones on the expression of E-cadherin
in irradiated lung tissue was investigated.
Soy isoflavones have been shown to have anti-inflammatory properties in chronic
inflammation and cardiovascular disease (164). Chacko et. al. demonstrated that anti-
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inflammatory mechanisms of soy isoflavones include modulation of leukocyte-endothelial cell
interactions in an in vitro blood flow assay as well as pro-inflammatory cytokine inhibition that
was dependent on activation of peroxisome proliferator-activated receptor (PPAR-γ) (107).
Genistein has been shown to down-regulate cytokine-induced pro-inflammatory pathways in
human brain microvascular endothelial cells (106). The microenvironment in which a cytokine is
released contributes to the function of that particular cytokine. Therefore, the timing and context
of the milieu into which a particular cytokine is released determines functional outcome.
In chapters 2 and 3, we focused on cellular mediators of radioprotection by soy
isoflavones in normal lung. In this final chapter, we further study the modulation of
inflammatory response by soy isoflavones in irradiated lungs by investigating potential
molecular mechanisms involved in soy radioprotection.
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MATERIALS AND METHODS

Mice
Female BALB/c mice (Harlan, Indianapolis, IN) 5-6 weeks old, were housed and handled
in animal facilities accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care. The animal protocol was approved by Wayne State University
Institutional Animal Care and Use Committee.

Soy isoflavones
The soy isoflavone mixture G-4660 used is a pure extract of 98.16% isoflavones from
soybeans consisting of 83.3% genistein, 14.6% daidzein and 0.26% glycitein (manufactured by
Organic Technologies and obtained from the National Institutes of Health [NIH], Bethesda,
MD). The soy isoflavone mixture was dissolved in DMSO and mixed with sesame seed oil at a
1:20 ratio just prior to treatment to facilitate gavage and avoid irritation of the esophagus by
DMSO (36, 134, 135).

Lung irradiation
Radiation was delivered to the thoracic cage comprising the whole lung. Three
anesthetized mice, in jigs, were positioned under a 6.4 mm lead shield with 3 cut-outs in an
aluminum frame mounted on the X-ray machine to permit selective irradiation of the lung in 3
mice at a time, as previously described (134). The radiation dose to the lung and the scattered
dose to areas of the mouse outside of the radiation field were carefully monitored. To minimize
backscattering of radiation, the bottom of the aluminum frame that holds the jigs was hollowed
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out and the backplate of the jig was thinned to 1.6mm thickness. Under these conditions and the
lead shielding, the X ray dose to the shielded regions was reduced to 1% of the dose to the
irradiated field. The dose rate was 101 cGy/min and half value layer was 2 mm Cu. Photon
irradiation was performed at a dose of 10 Gy with a Siemens Stabilipan X-ray set (Siemens
Medical Systems, Inc., Erlangen, Germany) operated at 250 kV, 15 mA with 1 mm copper
filtration at a distance of 47.5 cm from the target.

Experimental Design
Mice were pre-treated with oral soy isoflavones each day for 3 days at a dose of 5mg/day
(equivalent to 250mg/kg). Then, the lung was selectively irradiated with 10 Gy. Soy treatment
was continued on a daily basis for 5 more days at 5mg/day. Then mice were treated with a lower
soy dose of 1mg/day (equivalent to 50mg/kg), given daily 5 days a week for up to 18 weeks. The
rationale for giving a higher dose of soy isoflavones for pre-treatment and just after radiation is
to optimize the effect of soy, based on previous studies (36, 140). At different time points,
separate mice from each treatment group were either homogenized for ELISA, snap frozen for
western blot, or mice were used to fix lungs in situ with formalin for histology studies as detailed
below.

Preparation of Lung Tissue Protein Lysates and Western Blot Analysis
Mice were sacrificed at 12 and 18 weeks post-irradiation. Lungs were resected and snap
frozen. To prepare lung tissue protein lysates, frozen lungs were thawed, weighed, and
homogenized in 10% w/v of lysis buffer using a gentleMACS tissue dissociator (Miltenyi Biotec,
Bergisch, Germany). The suspension was centrifuged at 4000 x g for 5 minutes at 4°C and the
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protein extracts were frozen at -80°C until analysis. For western blot analysis, total lung protein
extracts (50 µg) were loaded and separated on 10% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to Whatman membranes (GE Healthcare Life
Sciences, Pittsburgh, PA). Membranes were incubated with anti-NF-κB p65 antibody
(eBioscience, Sn Diego, CA; 1:200) overnight at 4°C. Membranes were washed and incubated
with horseradish peroxidase-conjugated secondary antibody (Vector Labs, 1:2000) at room
temperature for 1 hour. Immunoreactive protein bands were visualized by SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific, Waltham, MA) and captured on a digital
imaging system (Fotodyne Inc., Hartland, WI). Membranes were re-probed with anti-β-actin Ab
as a loading control.15

Immunohistochemistry (IHC)
Mice were sacrificed and lungs were intratracheally instilled with 10% buffered formalin
and resected, embedded in paraffin, and sectioned. Sections were blocked with IHC Tek
Antibody Diluent (IHC World, Woodstock, MD) then incubated with primary purified
monoclonal antibodies directed against epithelial cadherin (E-cadherin) or peroxisome
proliferator-activated receptor (PPAR-γ) (eBioscience, San Diego, CA) overnight at 4° C. Lung
sections were then incubated with biotinylated secondary antibodies (Vector Labs, Burlingame,
CA) at 1:300 for 1 hour at room temperature. Staining was amplified with the avidin-biotin
system Vectastain ABC Reagent Kit (Vector Labs) and visualized with the Vector DAB
Substrate Kit for peroxidase (Vector Labs). Sections were counterstained with IHC-Tek Mayer’s
Hematoxylin (IHC World, Woodstock, MD) and mounted with Permount mounting media
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(Electron Microscopy Sciences, Hatfield, PA). Arg-1 expression in lung tissue after radiation
was evaluated on a Nikon E800 microscope (Nikon Inc., Melville, NY).

Enzyme-linked immunosorbant assay (ELISA)
Mice were sacrificed at various time points between 0-18 weeks post-irradiation. Lungs
were resected and snap frozen. To prepare lung homogenates, frozen lungs were thawed,
weighed, and homogenized in 10% w/v of phosphate buffered saline (PBS) with Complete
Protease Inhibitor Cocktail Tablets (Roche Diagnostics, Indianapolis, IN) using a gentleMACS
tissue dissociator (Miltenyi Biotec, San Diego, CA). The suspension was centrifuged at 4000 x g
for 5 minutes at 4°C and the supernatant was frozen at -80°C. Lung homogenates were assayed
IL-1α, IL-1β, IL-4, IL-6, IL-10, IL-13, IL-15, IL-17A, TNF-α, TGF-β, IFN-γ, and CCL2 using
the respective Ready-SET-GO ELISA kits (eBioscience, San Diego, CA) according to
manufacturer’s instructions.
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RESULTS

Effect of radiation and soy isoflavones on E-cadherin levels in lung tissue. Radiation can
compromise endothelial and epithelial cell barrier integrity by interrupting adherens junctions
that bind cells together within tissues. E-cadherin is an adhesion molecule expressed on epithelial
cells (48). We previously showed that radiation-induced cytokines were decreased by soy
isoflavones at 4 weeks post-irradiation, and thus we aimed to determine whether radiation
affected cell barrier integrity at this same time point. Lung tissue sections were obtained from
control mice and mice treated with radiation or radiation + soy isoflavones at 4 weeks after
radiation and stained by IHC with E-cadherin. Staining of E-cadherin showed that radiation
caused a pronounced loss in positive staining in areas of thickened septa (Figure 4.1). In contrast,
following radiation + soy isoflavones treatment, considerably higher levels of positive staining
for E-cadherin were observed, compared to radiation-treated lungs (Figure 4.1).
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Figure 4.1. In situ detection of E-cadherin in lung tissue at 4 weeks after radiation ± soy
isoflavones. Lungs tissue sections were obtained from control (Con) mice and mice treated with
radiation (Rad) or radiation + soy (Rad+Soy) at 4 weeks after radiation. Sections were stained by
IHC for E-cadherin to detect expression in situ. Staining of E-cadherin showed that radiation
caused a pronounced decrease in positive staining in areas of thickened septa at 4 weeks after
radiation. In contrast, following radiation + soy treatment, considerably higher levels of positive
staining for E-cadherin were observed, compared to radiation-treated lungs. Secondary antibody
alone is shown as a staining control. All magnifications are at 40x.
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Effect of radiation and soy isoflavones on cytokine levels in lung tissue. The effect of soy
isoflavones on the kinetics of molecular meditors of the immune system triggered by radiaiton
were evaluated in lungs. Cytokine and chemokine levels following radiation were measured over
time by ELISA in lung homogenates obtained mice. Pro-inflammatory cytokine levels associated
with Th1/M1 immune responses were evaluated over time after a single dose of thoracic
radiation (Figure 4.2). Soy isoflavones inhibited pro-inflammatory cytokines induced by
radiation, including IL-1β, IL-6, TNF-α, and IFN-γ (Figure 4.2). Additionally, treatment with soy
isoflavones increased IL-1β and IFN-γ at early time points of 4-24 hours post-radiation, which
could play an anti-fibrotic role in the irradiated lung (Figure 4.2). There are minimal differences
in the kinetics of cytokines and chemokine levels associated with Th2/M2 immune responses in
lungs harvested from mice treated with radiation compared to radiation + soy (Figure 4.3).
Cytokine and chemokine levels in lungs from mice receiving daily soy isoflavones
treatment or age matched controls revealed that, in general, soy isoflavones alone did not alter
the cytokine or chemokine profile (Figure 4.4). This finding implies that soy isoflavones tend to
modulate the immune system once an inflammatory insult has triggered the activation of
pathways assoaciated with inflammation in cells and tissues.
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Figure 4.2. Effect of soy isoflavones on the kinetics of Th1/M1 anti-inflammatory cytokine
profile in irradiated lung tissue. Cytokine and chemokine levels associated with Th1/M1
immune responses following radiation were measured over time by ELISA in lung homogenates
obtained from mice.
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Figure 4.3. Effect of soy isoflavones on the kinetics of Th2/M2 anti-inflammatory cytokine
profile in irradiated lung tissue. Cytokine levels associated with Th2/M2 immune responses
following radiation were measured over time by ELISA in lung homogenates obtained from
mice. ND = not detectable.
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Figure 4.4. Effect of soy isoflavones treatment on homeostatic cytokine profile in lung
tissue. Cytokine and chemokine levels associated with Th1/M1 or Th2/M2 immune responses
were measured over time by ELISA in lung homogenates obtained mice receiving daily soy
isoflavones treatment or age matched controls. In general, soy isoflavones alone did not alter the
cytokine or chemokine profile.
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Effect of radiation and soy isoflavones on PPAR-γ in lung tissue. PPAR-γ plays a role in M2
macrophage differentiation and activation (165). Expression of PPAR-γ in whole lung tissue as
determined by western blot was increased after in both radiation-treated and radiation + soytreated lungs (Figure 4.5A). To further evaluate the effect of soy isoflavones on the radiationinduced increase of PPAR- γ in lungs, tissue sections were obtained from control mice and mice
treated with radiation or radiation + soy isoflavones at 18 weeks after radiation and stained with
PPAR- γ. Interestingly, soy isoflavones altered cellular localization of PPAR-γ in alveolar
macrophages at 18 weeks post-radiation. Alveolar macrophages showed cytoplasmic localization
of PPAR-γ following radiation, in contrast to nuclear localization following supplementation
with soy isoflavones (Figure 4.5B). Radiation caused a marked increase in PPAR-γ+
macrophages in thickened alveolar septa areas and spaces. Numerous alveolar macrophages
showing the morphology of activated macrophages were particularly enlarged with abundant
positive cytoplasmic staining compared to small macrophages in control lungs (arrows). The
density of PPAR-γ+ macrophages was much lower in radiation + soy treated lungs at 18 weeks
after radiation compared to radiation–treated lungs. Alveolar macrophages were also smaller,
resembling those of control lungs and PPAR-γ positivity was more prominent in the nucleus
rather than the cytoplasm, as compared to radiation–treated lungs.
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Figure 4.5. Soy isoflavones alter cellular localization of PPAR-γ in alveolar macrophages at
18 weeks post-radiation. (A). Western blot analysis of PPAR-γ on whole tissue lysates obtained
from lungs showed an increase induced by radiation, including in irradiate lungs treated with soy
isoflavones. Band intensities were quantified using ImageJ (NIH) densitometry analysis. (B).
Lung tissue sections were obtained from control (Con) mice and mice treated with radiation
(Rad) or radiation + soy (Rad+Soy) at 18 weeks after radiation. Lung sections were stained by
IHC for PPAR-γ. Arrows indicate intense cytoplasmic PPAR-γ staining of alveolar
macrophages. Radiation caused a marked increase in PPAR-γ+ macrophages in thickened areas
of septa and in alveolar spaces. Numerous alveolar macrophages showing the morphology of
activated macrophages were particularly enlarged with abundant positive cytoplasmic staining
compared to small macrophages in control lungs (arrows). The density of PPAR-γ+ macrophages
was much lower in radiation + soy treated lungs at 18 weeks after radiation compared to
radiation–treated lungs. Alveolar macrophages were also smaller, resembling those of control
lungs and PPAR-γ positivity was more prominent in the nucleus compared to radiation–treated
lungs.
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Effect of radiation and soy isoflavones on NF-κB in lung tissue. NF-κB promotes M1
macrophage pro-inflammatory gene expression (166), and we have reported that radiation
upregulates that constitutively active NF-κB is in prostate cancer cells (167). Western blot
analysis of normal lung tissue obtained from mice treated with radiation and/or soy isoflavones
revealed that NF-κB levels were increased by radiation and was inhibited by the addition of soy
isoflavones at 12 weeks (Figure 4.6A) and 18 weeks (Figure 4.6B) post-radiation.
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Figure 4.6. Soy isoflavones inhibit radiation-induced increase of NF-κB p65 subunit levels
in lung tissue. Lungs tissue sections were obtained from control (Con) mice and mice treated
with radiation (Rad) or radiation + soy (Rad+Soy) at 12 and 18 weeks after radiation. (A).
Western blot analysis of NF-κB p65 on whole tissue lysates obtained from lungs at 12 weeks
post-radiation showed an increase induced by radiation, which was inhibited by the addition of
soy isoflavones. (B). An increase in NF-κB p65 was also observed at 18 weeks post-radiation,
and an even more dramatic decrease in NF-κB p65 levels was detected in the lung at this later
time point with the addition of soy isoflavones. Band intensities were quantified using ImageJ
(NIH) densitometry analysis.
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DISCUSSION

Radiation can compromise endothelial and epithelial cell barrier integrity by interrupting
adherens junctions that bind cells together within tissues. E-cadherin is a cell-cell adhesion
molecule expressed on epithelial cells (48). Normal expression of E-cadherin is critical for the
maintenance of tight junctions between epithelial cells and for maintenance of normal barrier
function of airway epithelium. A reduction in the lung expression of E-cadherin is indicative of a
damaged, disrupted epithelial barrier that can drive recruitment of inflammatory cells and
promote a cascade of damage-associated molecular events and chronic inflammation. At 4 weeks
post-irradiation, we found a pronounced loss in E-cadherin in areas of thickened septa by IHC. In
contrast, following radiation + soy treatment, considerably higher levels of positive staining for
E-cadherin were observed, compared to radiation-treated lungs. These data suggest that soy
isoflavones maintain the cell-cell junctions important for proper tissue integrity in normal lung
that are damaged by thoracic irradiation.
Cytokine levels in lung homogenates of irradiated mice increase by 3-6 hours after
radiation in correlation with levels measured in serum (162). The microenvironment in which a
cytokine is released contributes to the function of that particular cytokine. Therefore, the timing
and context of the milieu that a particular cytokine is released in determines functional outcome.
The cytokine TGF-β is a canonical cytokine involved in driving fibrosis (168), whereas the
cytokines IL-1β, IFN-γ, and TNF-α can play an anti-fibrotic role (169, 170). Interestingly, our
model did not reveal a radiation-induced increase in TGF-β after radiation, even at a late time
point of 18 week post-radiation, indicating that TGF-β may not play a pivotal role in RILI and
fibrosis in our model.
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Nuclear factor κB (NF-κB) activation is a molecular common denominator between
inflammation and cancer (108). This transcription factor is constitutively active in a large
number of cancers and is critical for tumor cell survival. Our lab has previously shown that soy
isoflavones target critical survival pathways that are upregulated or constitutively activated in
cancer cells, including NF-κB, which are responsible for the transcription (109). In contrast,
normal cells do not constitutively express NF-κB, and activation of this transcription factor is
important for the expression of pro-inflammatory gene programs. We confirmed in vivo in naïve
mice that soy isoflavones inhibited radiation-induced NF-κB increase in the lung at 12 and 18
weeks post-irradiation. NF-κB promotes M1 macrophage pro-inflammatory gene expression
(166). Peroxisomal proliferator-activated receptors (PPAR-α, β, δ, and γ) are ligand-activated
transcription factors that heterodimerize with retinoid X receptor (RXR) to results gene
expression (171). Promoting PPAR-γ activation by its cognate ligands have been shown to
mitigate lung injury and fibrosis (172, 173). Soy isoflavones, in particular genistein, are known
PPAR-γ ligands (174). PPAR-γ can influence the downregulation of pro-inflammatory mediators
via trans-repression of NF-κB (175). Soy isoflavones may promote anti-inflammatory gene
expression programs in the lung after thoracic radiation by interacting with PPAR-γ and
downregulation of NF-κB.
In summary, our pre-clinical study in lung suggests that a radioprotective mechanism of
soy isoflavones could involve the promotion of intact epithelial and endothelial tight junctions
that are damaged after radiation via E-cadherin, resulting in subsequent downregulation of tissue
damaging inflammation. Additionally, soy isoflavones may downregulate pro-inflammatory gene
programs and cytokine expression upregulated by radiation-induced increases of NF-κB in
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normal tissue, while promoting anti-inflammatory or repair pathways via the interaction of soy
isoflavones with PPAR-γ.
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GENERAL CONCLUSIONS

Chemoradiotherapy is currently the standard of care for unresectable locally advanced
non-small cell lung carcinoma (NSCLC). However, the treatment success for this patient
population has been severely constrained by post-therapy toxicity, presenting as pneumonitis and
later fibrosis (176, 177). Conventional fractionated radiotherapy is associated with normal tissue
side effects and poor quality of life (22). Hypofractionated radiotherapy is an emerging modality
for early-stage lung cancer, which can utilize a high radiation dose per fraction over a relatively
short time period to improve effectiveness of tumor destruction and increase convenience by
reducing the number of visits for therapy (178-180). However, high intensity radiotherapy can
also be associated with greater damage to lung tissue, emphasizing the need to develop
complementary approaches to alleviate radiation-induced injury to normal lung structures and
function (60).
Our pre-clinical murine studies (36, 134, 135) have already revealed that oral
administration of a mixture of the soy isoflavones genistein, daidzein, and glycitein can enhance
lung tumor eradication and simultaneously protect normal lung from radiation injury. While the
anti-oxidant and disease preventative effects of a soy-rich diet have been investigated, prior to
this dissertation project an immune-mediated mechanism of radioprotection by soy isoflavones
in normal tissues remained to be elucidated.
This dissertation has focused on investigating mechanisms of radioprotection mediated
by soy isoflavones in normal lung tissue by dissecting the effect of soy supplementation on the
radiation-induced inflammatory responses and immunosuppressive and repair pathways in
irradiated lungs. Radiation therapy triggers a potent inflammatory response is a key contributor
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to the tissue-damaging pathology of RILI. Our preclinical studies in lung cancer models and
naïve mice indicate that soy isoflavones inhibit this inflammatory process or even promote tissue
repair.
In summary, our pre-clinical studies in lung suggest that a radioprotective mechanism of
soy isoflavones likely involves both the inhibition of infiltration and activation of macrophages
and neutrophils in irradiated lungs as well as the promotion of immunosuppressive myeloidderived suppressor cells (Figure 5). Soy isoflavones inhibited the radiation-induced infiltration
and activation of macrophages and neutrophils in the lung, and polarized lung macrophages from
M1 to M2 macrophage phenotype. Soy inhibited alveolar macrophage activation in
bronchoalveolar spaces induced by radiation and had a protective effect on regulatory interstitial
macrophages that could participate in maintaining lung homeostasis and control inflammation
and tissue damage. We also show that treatment with soy isoflavones downregulates proinflammatory gene programs and cytokine expression that are upregulated by radiation-induced
increases of NF-κB in normal tissue, and may upregulating anti-inflammatory pathways via the
interaction of isoflavones with PPAR-γ. Furthermore, soy isoflavones also promoted intact
epithelial and endothelial tight junctions via E-cadherin that are damaged after radiation and
granulocytic myeloid-derived suppressor cells that express Arg-1 after radiation, resulting in
subsequent dampening of tissue damaging inflammation. These findings serve as potential
mechanisms of soy-mediated radioprotection in normal lung, contributing to the resolution of
radiation-induced acute and chronic inflammation that lead to pneumonitis and fibrosis.
The clinical goal is to improve the therapeutic ratio of high-dose radiation therapy on the
tumor target and reduce the radiation dose-limiting toxicity of radiation therapy to the normal
lung. These findings suggest that soy isoflavones used as a complementary intervention to

97

radiotherapy for lung cancer could potentially reduce lung toxicity and provide improved
therapeutic benefit to patients.
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Figure 5. General conclusions and overall hypothesis. A single dose of thoracic irradiation
triggers inflammatory responses in the lung that include increased NF-κB and pro-inflammatory
cytokine production, as well as increases in the infiltration and activation of macrophages and
neutrophils. Our findings suggest that soy can inhibit the infiltration and activation of
macrophages and neutrophils induced by radiation in bronchoalveolar spaces and the lung
parenchyma. Radiation induced a pro-inflammatory M1 macrophage phenotype in lungs, while
mice receiving soy isoflavones and radiation switched to an anti-inflammatory M2 macrophage
subtype. Soy isoflavones inhibited the radiation-induced upregulation of NF-κB and proinflammatory cytokine release in the lung. Soy isoflavones also had a protective effect on
regulatory interstitial macrophages (IM) after irradiation and Arg-1+ granulocytic MDSCs, while
inhibiting alveolar macrophage (AM) activation induced by radiation. These data indicate that a
mechanism of radioprotection by soy isoflavones in normal lung includes the modulation of
innate immune cellular and molecular mediators of the inflammatory response induced by
radiation.

99

REFERENCES

1.

Keane MP, Belperio JA, Henson PM, Strieter RM. 2005. Inflammation, injury, and
repair, p. 449-490. In Murray JF, Nadel JA, Mason RJ, Broaddus VC (ed.), Textbook of
respiratory medicine, 4th ed. Elsevier Saunders, Philadelphia, PA.

2.

Effros RM. 2006. Anatomy, development, and physiology of the lungs. GI Motility
online.

3.

Tschernig T, Pabst R. 2009. What is the clinical relevance of different lung
compartments? BMC Pulm Med 9:39.

4.

Martin TR, Frevert CW. 2005. Innate immunity in the lungs. Proc Am Thorac Soc
2:403-411.

5.

Hussain AN. 2006. Immune system of the lungs, p. 366-368, Pathologic Basis of
Disease.

6.

Guilliams M, De Kleer I, Henri S, Post S, Vanhoutte L, De Prijck S, Deswarte K,
Malissen B, Hammad H, Lambrecht BN. 2013. Alveolar macrophages develop from
fetal monocytes that differentiate into long-lived cells in the first week of life via GMCSF. J Exp Med 210:1977-1992.

7.

Lambrecht BN. 2006. Alveolar macrophage in the driver's seat. Immunity 24:366-368.

8.

Holt PG. 1978. Inhibitory activity of unstimulated alveolar macrophages on Tlymphocyte blastogenic response. Am Rev Respir Dis 118:791-793.

9.

Roberts LM, Ledvina HE, Tuladhar S, Rana D, Steele SP, Sempowski GD,
Frelinger JA. 2015. Depletion of alveolar macrophages in CD11c diphtheria toxin
receptor mice produces an inflammatory response. Immun Inflamm Dis 3:71-81.

100

10.

Kruger P, Saffarzadeh M, Weber AN, Rieber N, Radsak M, von Bernuth H,
Benarafa C, Roos D, Skokowa J, Hartl D. 2015. Neutrophils: Between host defence,
immune modulation, and tissue injury. PLoS Pathog 11:e1004651.

11.

Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, Chilvers ER. 2010.
Neutrophil kinetics in health and disease. Trends Immunol 31:318-324.

12.

Ringborg U, Bergqvist D, Brorsson B, Cavallin-Stahl E, Ceberg J, Einhorn N,
Frodin JE, Jarhult J, Lamnevik G, Lindholm C, Littbrand B, Norlund A, Nylen U,
Rosen M, Svensson H, Moller TR. 2003. The Swedish Council on Technology
Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer
including a prospective survey of radiotherapy practice in Sweden 2001--summary and
conclusions. Acta Oncol 42:357-365.

13.

Coggle JE, Lambert BE, Moores SR. 1986. Radiation effects in the lung. Environ
Health Perspect 70:261-291.

14.

Stone HB, Coleman CN, Anscher MS, McBride WH. 2003. Effects of radiation on
normal tissue: consequences and mechanisms. Lancet Oncol 4:529-536.

15.

Rubin P, Casarett GW. 1968. Clinical radiation pathology as applied to curative
radiotherapy. Cancer 22:767-778.

16.

Dörr W. 2009. Pathogenesis of normal-tissue side-effects, p. 169-190. In Joiner M, van
der Kogel A (ed.), Basic Clinical Radiobiology Fourth Edition. CRC Press.

17.

Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, Burnet
NG. 2009. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by
genotype. Nat Rev Cancer 9:134-142.

101

18.

van Meerbeeck JP, Meersschout S, De Pauw R, Madani I, De Neve W. 2008. Modern
radiotherapy as part of combined modality treatment in locally advanced non-small cell
lung cancer: present status and future prospects. Oncologist 13:700-708.

19.

Bradley JD, Bae K, Graham MV, Byhardt R, Govindan R, Fowler J, Purdy JA,
Michalski JM, Gore E, Choy H. 2010. Primary analysis of the phase II component of a
phase I/II dose intensification study using three-dimensional conformal radiation therapy
and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer:
RTOG 0117. J Clin Oncol 28:2475-2480.

20.

Kelsey CR, Rosenstein BS, Marks LB. 2012. Predicting toxicity from radiation
therapy--it's genetic, right? Cancer 118:3450-3454.

21.

Schallenkamp JM, Miller RC, Brinkmann DH, Foote T, Garces YI. 2007. Incidence
of radiation pneumonitis after thoracic irradiation: Dose-volume correlates. Int J Radiat
Oncol Biol Phys 67:410-416.

22.

Williams JP, Johnston CJ, Finkelstein JN. 2010. Treatment for radiation-induced
pulmonary late effects: spoiled for choice or looking in the wrong direction? Curr Drug
Targets 11:1386-1394.

23.

Kong FM, Hayman JA, Griffith KA, Kalemkerian GP, Arenberg D, Lyons S,
Turrisi A, Lichter A, Fraass B, Eisbruch A, Lawrence TS, Ten Haken RK. 2006.
Final toxicity results of a radiation-dose escalation study in patients with non-small-cell
lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat
Oncol Biol Phys 65:1075-1086.

102

24.

Robnett TJ, Machtay M, Vines EF, McKenna MG, Algazy KM, McKenna WG.
2000. Factors predicting severe radiation pneumonitis in patients receiving definitive
chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 48:89-94.

25.

McDonald S, Rubin P, Phillips TL, Marks LB. 1995. Injury to the lung from cancer
therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J
Radiat Oncol Biol Phys 31:1187-1203.

26.

Choi YW, Munden RF, Erasmus JJ, Park KJ, Chung WK, Jeon SC, Park CK. 2004.
Effects of radiation therapy on the lung: radiologic appearances and differential
diagnosis. Radiographics 24:985-997; discussion 998.

27.

Morgan GW, Breit SN. 1995. Radiation and the lung: a reevaluation of the mechanisms
mediating pulmonary injury. Int J Radiat Oncol Biol Phys 31:361-369.

28.

Ghafoori P, Marks LB, Vujaskovic Z, Kelsey CR. 2008. Radiation-induced lung
injury. Assessment, management, and prevention. Oncology 22:37-47; discussion 52-33.

29.

Hill RP. 2005. Radiation effects on the respiratory system. The British Journal of
Radiology Supplement_27:75-81.

30.

Bentzen SM. 2006. Preventing or reducing late side effects of radiation therapy:
radiobiology meets molecular pathology. Nat Rev Cancer 6:702-713.

31.

Strieter RM. 2008. What differentiates normal lung repair and fibrosis? Inflammation,
resolution of repair, and fibrosis. Proc Am Thorac Soc 5:305-310.

32.

Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN. 1995. A perpetual
cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol
Phys 33:99-109.

103

33.

Burger A, Loffler H, Bamberg M, Rodemann HP. 1998. Molecular and cellular basis
of radiation fibrosis. Int J Radiat Biol 73:401-408.

34.

Rubin P, Finkelstein J, Shapiro D. 1992. Molecular biology mechanisms in the
radiation induction of pulmonary injury syndromes: interrelationship between the
alveolar macrophage and the septal fibroblast. Int J Radiat Oncol Biol Phys 24:93-101.

35.

Tsoutsou PG, Koukourakis MI. 2006. Radiation pneumonitis and fibrosis: mechanisms
underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol
Phys 66:1281-1293.

36.

Hillman GG, Singh-Gupta V, Runyan L, Yunker CK, Rakowski JT, Sarkar FH,
Miller S, Gadgeel SM, Sethi S, Joiner MC, Konski AA. 2011. Soy isoflavones
radiosensitize lung cancer while mitigating normal tissue injury. Radiother Oncol
101:329-336.

37.

Franke-Ullmann G, Pfortner C, Walter P, Steinmuller C, Lohmann-Matthes ML,
Kobzik L. 1996. Characterization of murine lung interstitial macrophages in comparison
with alveolar macrophages in vitro. J Immunol 157:3097-3104.

38.

Laskin DL, Weinberger B, Laskin JD. 2001. Functional heterogeneity in liver and lung
macrophages. J Leukoc Biol 70:163-170.

39.

Franko AJ, Sharplin J. 1994. Development of fibrosis after lung irradiation in relation
to inflammation and lung function in a mouse strain prone to fibrosis. Radiat Res
140:347-355.

40.

Ricardo SD, van Goor H, Eddy AA. 2008. Macrophage diversity in renal injury and
repair. J Clin Invest 118:3522-3530.

104

41.

Mosser DM, Edwards JP. 2008. Exploring the full spectrum of macrophage activation.
Nat Rev Immunol 8:958-969.

42.

Barbul A. 2008. Proline precursors to sustain Mammalian collagen synthesis. J Nutr
138:2021S-2024S.

43.

Deonarine K, Panelli MC, Stashower ME, Jin P, Smith K, Slade HB, Norwood C,
Wang E, Marincola FM, Stroncek DF. 2007. Gene expression profiling of cutaneous
wound healing. J Transl Med 5:11.

44.

Grommes J, Soehnlein O. 2011. Contribution of neutrophils to acute lung injury. Mol
Med 17:293-307.

45.

Bradley PP, Priebat DA, Christensen RD, Rothstein G. 1982. Measurement of
cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J
Invest Dermatol 78:206-209.

46.

Haston CK, Begin M, Dorion G, Cory SM. 2007. Distinct loci influence radiationinduced alveolitis from fibrosing alveolitis in the mouse. Cancer research 67:1079610803.

47.

Sener G, Jahovic N, Tosun O, Atasoy BM, Yegen BC. 2003. Melatonin ameliorates
ionizing radiation-induced oxidative organ damage in rats. Life Sci 74:563-572.

48.

Takeichi M. 1991. Cadherin cell adhesion receptors as a morphogenetic regulator.
Science 251:1451-1455.

49.

Kaur P, Asea A. 2012. Radiation-induced effects and the immune system in cancer.
Front Oncol 2:191.

50.

Eckes B, Zigrino P, Kessler D, Holtkotter O, Shephard P, Mauch C, Krieg T. 2000.
Fibroblast-matrix interactions in wound healing and fibrosis. Matrix Biol 19:325-332.

105

51.

Thannickal VJ, Toews GB, White ES, Lynch JP, 3rd, Martinez FJ. 2004.
Mechanisms of pulmonary fibrosis. Annu Rev Med 55:395-417.

52.

Thompson HG, Mih JD, Krasieva TB, Tromberg BJ, George SC. 2006. Epithelialderived TGF-beta2 modulates basal and wound-healing subepithelial matrix homeostasis.
Am J Physiol Lung Cell Mol Physiol 291:L1277-1285.

53.

Khalil N, Bereznay O, Sporn M, Greenberg AH. 1989. Macrophage production of
transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary
inflammation. J Exp Med 170:727-737.

54.

Penn JW, Grobbelaar AO, Rolfe KJ. 2012. The role of the TGF-beta family in wound
healing, burns and scarring: a review. Int J Burns Trauma 2:18-28.

55.

Vujaskovic Z, Groen HJ. 2000. TGF-beta, radiation-induced pulmonary injury and lung
cancer. Int J Radiat Biol 76:511-516.

56.

Anscher MS, Kong FM, Andrews K, Clough R, Marks LB, Bentel G, Jirtle RL.
1998. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis.
Int J Radiat Oncol Biol Phys 41:1029-1035.

57.

Fu XL, Huang H, Bentel G, Clough R, Jirtle RL, Kong FM, Marks LB, Anscher
MS. 2001. Predicting the risk of symptomatic radiation-induced lung injury using both
the physical and biologic parameters V(30) and transforming growth factor beta. Int J
Radiat Oncol Biol Phys 50:899-908.

58.

De Jaeger K, Seppenwoolde Y, Kampinga HH, Boersma LJ, Belderbos JS,
Lebesque JV. 2004. Significance of plasma transforming growth factor-beta levels in
radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58:1378-1387.

106

59.

Brizel DM. 2007. Pharmacologic approaches to radiation protection. J Clin Oncol
25:4084-4089.

60.

Prasanna PG, Stone HB, Wong RS, Capala J, Bernhard EJ, Vikram B, Coleman
CN. 2012. Normal tissue protection for improving radiotherapy: Where are the Gaps?
Transl Cancer Res 1:35-48.

61.

Citrin D, Cotrim AP, Hyodo F, Baum BJ, Krishna MC, Mitchell JB. 2010.
Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist
15:360-371.

62.

Kwok E, Chan CK. 1998. Corticosteroids and azathioprine do not prevent radiationinduced lung injury. Can Respir J 5:211-214.

63.

Ward HE, Kemsley L, Davies L, Holecek M, Berend N. 1993. The effect of steroids
on radiation-induced lung disease in the rat. Radiat Res 136:22-28.

64.

Abratt RP, Morgan GW, Silvestri G, Willcox P. 2004. Pulmonary complications of
radiation therapy. Clin Chest Med 25:167-177.

65.

Bonnans C, Chou J, Werb Z. 2014. Remodelling the extracellular matrix in
development and disease. Nat Rev Mol Cell Biol 15:786-801.

66.

Okunieff P, Augustine E, Hicks JE, Cornelison TL, Altemus RM, Naydich BG, Ding
I, Huser AK, Abraham EH, Smith JJ, Coleman N, Gerber LH. 2004. Pentoxifylline
in the treatment of radiation-induced fibrosis. J Clin Oncol 22:2207-2213.

67.

Neuner P, Klosner G, Schauer E, Pourmojib M, Macheiner W, Grunwald C,
Knobler R, Schwarz A, Luger TA, Schwarz T. 1994. Pentoxifylline in vivo downregulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human
peripheral blood mononuclear cells. Immunology 83:262-267.

107

68.

Oliveira-Junior IS, Pinheiro BV, Silva ID, Salomao R, Zollner RL, Beppu OS. 2003.
Pentoxifylline decreases tumor necrosis factor and interleukin-1 during high tidal
volume. Braz J Med Biol Res 36:1349-1357.

69.

Rube CE, Wilfert F, Uthe D, Schmid KW, Knoop R, Willich N, Schuck A, Rube C.
2002. Modulation of radiation-induced tumour necrosis factor alpha (TNF-alpha)
expression in the lung tissue by pentoxifylline. Radiother Oncol 64:177-187.

70.

Ozturk B, Egehan I, Atavci S, Kitapci M. 2004. Pentoxifylline in prevention of
radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind
randomized trial. Int J Radiat Oncol Biol Phys 58:213-219.

71.

Sweitzer NK. 2003. Cardiology patient page. What is an angiotensin converting enzyme
inhibitor? Circulation 108:e16-18.

72.

Ward WF, Molteni A, Ts'ao CH. 1989. Radiation-induced endothelial dysfunction and
fibrosis in rat lung: modification by the angiotensin converting enzyme inhibitor
CL242817. Radiat Res 117:342-350.

73.

Kharofa J, Cohen EP, Tomic R, Xiang Q, Gore E. 2012. Decreased risk of radiation
pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors
and thoracic radiation therapy. Int J Radiat Oncol Biol Phys 84:238-243.

74.

Yuhas JM, Storer JB. 1969. Differential chemoprotection of normal and malignant
tissues. J Natl Cancer Inst 42:331-335.

75.

Kouvaris JR, Kouloulias VE, Vlahos LJ. 2007. Amifostine: the first selective-target
and broad-spectrum radioprotector. Oncologist 12:738-747.

76.

Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, Fossella FV,
Zinner R, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Kurie J, Herbst

108

R, Milas L, Ro J, Thames HD, Hong WK, Cox JD. 2002. Randomized phase III study
of chemoradiation with or without amifostine for patients with favorable performance
status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin
Radiat Oncol 12:46-49.
77.

Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F,
Zhang J, Russell L, Oster W, Sauer R. 2000. Phase III randomized trial of amifostine
as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345.

78.

Sanchez-Chino X, Jimenez-Martinez C, Davila-Ortiz G, Alvarez-Gonzalez I,
Madrigal-Bujaidar E. 2015. Nutrient and nonnutrient components of legumes, and its
chemopreventive activity: a review. Nutrition and cancer 67:401-410.

79.

Barnes S. 2010. The biochemistry, chemistry and physiology of the isoflavones in
soybeans and their food products. Lymphat Res Biol 8:89-98.

80.

Kang J, Badger TM, Ronis MJ, Wu X. 2010. Non-isoflavone phytochemicals in soy
and their health effects. J Agric Food Chem 58:8119-8133.

81.

Dakora FD, Joseph CM, Phillips DA. 1993. Alfalfa (Medicago sativa L.) Root
Exudates Contain Isoflavonoids in the Presence of Rhizobium meliloti. Plant Physiol
101:819-824.

82.

Rolfe BG. 1988. Flavones and isoflavones as inducing substances of legume nodulation.
BioFactors (Oxford) 1:3-10.

83.

Markiewicz L, Garey J, Adlercreutz H, Gurpide E. 1993. In vitro bioassays of nonsteroidal phytoestrogens. J Steroid Biochem Mol Biol 45:399-405.

109

84.

Branham WS, Dial SL, Moland CL, Hass BS, Blair RM, Fang H, Shi L, Tong W,
Perkins RG, Sheehan DM. 2002. Phytoestrogens and mycoestrogens bind to the rat
uterine estrogen receptor. J Nutr 132:658-664.

85.

Messina M. 2010. Isoflavones, p. 439-449. In Coates PM, Betz J, Blackman M, Cragg G,
Levine M, Moss J, White J (ed.), Encyclopedia of Dietary Supplemets. Informa
Healthcare, New York, NY.

86.

Shanle EK, Xu W. 2011. Endocrine disrupting chemicals targeting estrogen receptor
signaling: identification and mechanisms of action. Chem Res Toxicol 24:6-19.

87.

Omoni AO, Aluko RE. 2005. Soybean foods and their benefits: potential mechanisms of
action. Nutr Rev 63:272-283.

88.

Dakora FD, Phillips DA. 1996. Diverse functions of isoflavonoids in legumes transcend
anti-microbial definitions of phytoalexins. Physiological and Molecular Plant Pathology
49:1-20.

89.

Hsu A, Bray TM, Helferich WG, Doerge DR, Ho E. 2010. Differential effects of whole
soy extract and soy isoflavones on apoptosis in prostate cancer cells. Exp Biol Med
(Maywood) 235:90-97.

90.

Raffoul JJ, Banerjee S, Che M, Knoll ZE, Doerge DR, Abrams J, Kucuk O, Sarkar
FH, Hillman GG. 2007. Soy isoflavones enhance radiotherapy in a metastatic prostate
cancer model. Int J Cancer 120:2491-2498.

91.

Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS. 1998. Nutritional and
socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J
Natl Cancer Inst 90:1637-1647.

110

92.

Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van
der Burg B, Gustafsson JA. 1998. Interaction of estrogenic chemicals and
phytoestrogens with estrogen receptor beta. Endocrinology 139:4252-4263.

93.

Banerjee S, Li Y, Wang Z, Sarkar FH. 2008. Multi-targeted therapy of cancer by
genistein. Cancer Letters 269:226-242.

94.

Perabo FG, Von Low EC, Ellinger J, von Rucker A, Muller SC, Bastian PJ. 2008.
Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer
Prostatic Dis 11:6-12.

95.

Lee MM, Gomez SL, Chang JS, Wey M, Wang RT, Hsing AW. 2003. Soy and
isoflavone consumption in relation to prostate cancer risk in China. Cancer epidemiology,
biomarkers & prevention : a publication of the American Association for Cancer
Research, cosponsored by the American Society of Preventive Oncology 12:665-668.

96.

Holzbeierlein JM, McIntosh J, Thrasher JB. 2005. The role of soy phytoestrogens in
prostate cancer. Curr Opin Urol 15:17-22.

97.

Kurosu M. 2011. Biologically Active Molecules from Soybeans. In El-Shemy H (ed.),
Biologically Active Molecules from Soybeans, Soybean and Health.

98.

Day JK, Bauer AM, DesBordes C, Zhuang Y, Kim BE, Newton LG, Nehra V,
Forsee KM, MacDonald RS, Besch-Williford C, Huang TH, Lubahn DB. 2002.
Genistein alters methylation patterns in mice. J Nutr 132:2419S-2423S.

99.

Sit KH, Bay BH, Wong KP. 1993. Effect of genistein, a tyrosine-specific protein kinase
inhibitor, on cell rounding by pH upshifting. In Vitro Cell Dev Biol Anim 29A:395-402.

100.

Coward L, Smith M, Kirk M, Barnes S. 1998. Chemical modification of isoflavones in
soyfoods during cooking and processing. Am J Clin Nutr 68:1486S-1491S.

111

101.

Andres S, Abraham K, Appel KE, Lampen A. 2011. Risks and benefits of dietary
isoflavones for cancer. Crit Rev Toxicol 41:463-506.

102.

Day AJ, DuPont MS, Ridley S, Rhodes M, Rhodes MJ, Morgan MR, Williamson G.
1998. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine
and liver beta-glucosidase activity. FEBS Lett 436:71-75.

103.

Hendrich S. 2002. Bioavailability of isoflavones. J Chromatogr B Analyt Technol
Biomed Life Sci 777:203-210.

104.

Cooke PS, Selvaraj V, Yellayi S. 2006. Genistein, estrogen receptors, and the acquired
immune response. J Nutr 136:704-708.

105.

Cui S, Wienhoefer N, Bilitewski U. 2014. Genistein induces morphology change and
G2/M cell cycle arrest by inducing p38 MAPK activation in macrophages. Int
Immunopharmacol 18:142-150.

106.

Lee YW, Lee WH. 2008. Protective effects of genistein on proinflammatory pathways in
human brain microvascular endothelial cells. J Nutr Biochem 19:819-825.

107.

Chacko BK, Chandler RT, Mundhekar A, Khoo N, Pruitt HM, Kucik DF, Parks
DA, Kevil CG, Barnes S, Patel RP. 2005. Revealing anti-inflammatory mechanisms of
soy isoflavones by flow: modulation of leukocyte-endothelial cell interactions. Am J
Physiol Heart Circ Physiol 289:H908-915.

108.

Karin M. 2009. NF-kappaB as a critical link between inflammation and cancer. Cold
Spring Harb Perspect Biol 1:a000141.

109.

Hillman GG, Singh-Gupta V. 2011. Soy isoflavones sensitize cancer cells to
radiotherapy. Free Radic Biol Med 51:289-298.

112

110.

Chun OK, Chung SJ, Song WO. 2007. Estimated dietary flavonoid intake and major
food sources of U.S. adults. J Nutr 137:1244-1252.

111.

de Kleijn MJ, van der Schouw YT, Wilson PW, Adlercreutz H, Mazur W, Grobbee
DE, Jacques PF. 2001. Intake of dietary phytoestrogens is low in postmenopausal
women in the United States: the Framingham study(1-4). J Nutr 131:1826-1832.

112.

Mulligan AA, Welch AA, McTaggart AA, Bhaniani A, Bingham SA. 2007. Intakes
and sources of soya foods and isoflavones in a UK population cohort study (EPICNorfolk). Eur J Clin Nutr 61:248-254.

113.

Kim J, Kwon C. 2001. Estimated dietary isoflavone intake of Korean population based
on National Nutrition Survey. Nutr Res 21:947-953.

114.

Lee SA, Wen W, Xiang YB, Barnes S, Liu D, Cai Q, Zheng W, Shu XO. 2007.
Assessment of dietary isoflavone intake among middle-aged Chinese men. J Nutr
137:1011-1016.

115.

Liu Z, Li W, Sun J, Liu C, Zeng Q, Huang J, Yu B, Huo J. 2004. Intake of soy foods
and soy isoflavones by rural adult women in China. Asia Pac J Clin Nutr 13:204-209.

116.

Surh J, Kim MJ, Koh E, Kim YK, Kwon H. 2006. Estimated intakes of isoflavones
and coumestrol in Korean population. Int J Food Sci Nutr 57:325-344.

117.

Marugame T, Katanoda K. 2006. International comparisons of cumulative risk of
breast and prostate cancer, from cancer incidence in five continents Vol. VIII. Jpn J Clin
Oncol 36:399-400.

118.

Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M,
Fukami Y. 1987. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J
Biol Chem 262:5592-5595.

113

119.

Messina M. 2010. Insights gained from 20 years of soy research. J Nutr 140:2289S2295S.

120.

Bradbury RB, White DE. 1954. Estrogens and related substances in plants. Vitam Horm
12:207-233.

121.

Curnow DH. 1954. Oestrogenic activity of subterranean clover. II. The isolation of
genistein from subterranean clover and methods of quantitative estimation. Biochem J
58:283-287.

122.

Bennetts HW, Underwood EJ, Shier FL. 1946. A specific breeding problem of sheep
on subterranean clover pastures in Western Australia. Aust Vet J 22:2-12.

123.

Wakai K, Egami I, Kato K, Kawamura T, Tamakoshi A, Lin Y, Nakayama T, Wada
M, Ohno Y. 1999. Dietary intake and sources of isoflavones among Japanese. Nutrition
and cancer 33:139-145.

124.

Nagata C, Takatsuka N, Inaba S, Kawakami N, Shimizu H. 1998. Effect of soymilk
consumption on serum estrogen concentrations in premenopausal Japanese women. J
Natl Cancer Inst 90:1830-1835.

125.

Shu XO, Zheng Y, Cai H, Gu K, Chen Z, Zheng W, Lu W. 2009. Soy food intake and
breast cancer survival. Jama 302:2437-2443.

126.

Caan BJ, Natarajan L, Parker B, Gold EB, Thomson C, Newman V, Rock CL, Pu
M, Al-Delaimy W, Pierce JP. 2011. Soy food consumption and breast cancer prognosis.
Cancer epidemiology, biomarkers & prevention : a publication of the American
Association for Cancer Research, cosponsored by the American Society of Preventive
Oncology 20:854-858.

114

127.

Guha N, Kwan ML, Quesenberry CP, Jr., Weltzien EK, Castillo AL, Caan BJ. 2009.
Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the
Life After Cancer Epidemiology study. Breast cancer research and treatment 118:395405.

128.

Boyapati SM, Shu XO, Ruan ZX, Dai Q, Cai Q, Gao YT, Zheng W. 2005. Soyfood
intake and breast cancer survival: a followup of the Shanghai Breast Cancer Study. Breast
cancer research and treatment 92:11-17.

129.

Kang X, Zhang Q, Wang S, Huang X, Jin S. 2010. Effect of soy isoflavones on breast
cancer recurrence and death for patients receiving adjuvant endocrine therapy. CMAJ :
Canadian Medical Association journal = journal de l'Association medicale canadienne
182:1857-1862.

130.

Woo HD, Park KS, Ro J, Kim J. 2012. Differential influence of dietary soy intake on
the risk of breast cancer recurrence related to HER2 status. Nutrition and cancer 64:198205.

131.

Zhang YF, Kang HB, Li BL, Zhang RM. 2012. Positive effects of soy isoflavone food
on survival of breast cancer patients in China. Asian Pacific journal of cancer prevention
: APJCP 13:479-482.

132.

Chen M, Rao Y, Zheng Y, Wei S, Li Y, Guo T, Yin P. 2014. Association between soy
isoflavone intake and breast cancer risk for pre- and post-menopausal women: a metaanalysis of epidemiological studies. PloS one 9:e89288.

133.

Messina M, Caan BJ, Abrams DI, Hardy M, Maskarinec G. 2013. It's time for
clinicians to reconsider their proscription against the use of soyfoods by breast cancer
patients. Oncology 27:430-437.

115

134.

Hillman GG, Singh-Gupta V, Hoogstra DJ, Abernathy L, Rakowski J, Yunker CK,
Rothstein SE, Sarkar FH, Gadgeel S, Konski AA, Lonardo F, Joiner MC. 2013.
Differential effect of soy isoflavones in enhancing high intensity radiotherapy and
protecting lung tissue in a pre-clinical model of lung carcinoma. Radiother Oncol
109:117-125.

135.

Hillman GG, Singh-Gupta V, Lonardo F, Hoogstra DJ, Abernathy LM, Yunker
CK, Rothstein SE, Rakowski J, Sarkar FH, Gadgeel S, Konski AA, Joiner MC.
2013. Radioprotection of lung tissue by soy isoflavones. J Thorac Oncol 8:1356-1364.

136.

Mahmood J, Jelveh S, Zaidi A, Doctrow SR, Hill RP. 2013. Mitigation of radiationinduced lung injury with EUK-207 and genistein: effects in adolescent rats. Radiat Res
179:125-134.

137.

Singh-Gupta V, Joiner MC, Runyan L, Yunker CK, Sarkar FH, Miller S, Gadgeel
SM, Konski AA, Hillman GG. 2011. Soy isoflavones augment radiation effect by
inhibiting APE1/Ref-1 DNA repair activity in non-small cell lung cancer. J Thorac Oncol
6:688-698.

138.

Messina M, Kucuk O, Lampe JW. 2006. An overview of the health effects of
isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels.
J AOAC Int 89:1121-1134.

139.

Ahmad IU, Forman JD, Sarkar FH, Hillman GG, Heath E, Vaishampayan U, Cher
ML, Andic F, Rossi PJ, Kucuk O. 2010. Soy isoflavones in conjunction with radiation
therapy in patients with prostate cancer. Nutrition and cancer 62:996-1000.

140.

Hillman GG, Wang Y, Kucuk O, Che M, Doerge DR, Yudelev M, Joiner MC,
Marples B, Forman JD, Sarkar FH. 2004. Genistein potentiates inhibition of tumor

116

growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther 3:12711279.
141.

Hill RP, Zaidi A, Mahmood J, Jelveh S. 2011. Investigations into the role of
inflammation in normal tissue response to irradiation. Radiother Oncol 101:73-79.

142.

Mehta V. 2005. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung
cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys
63:5-24.

143.

Gough MJ, Young K, Crittenden M. 2013. The impact of the myeloid response to
radiation therapy. Clin Dev Immunol 2013:281958.

144.

Gensel JC, Zhang B. 2015. Macrophage activation and its role in repair and pathology
after spinal cord injury. Brain Res.

145.

Lucas T, Waisman A, Ranjan R, Roes J, Krieg T, Muller W, Roers A, Eming SA.
2010. Differential roles of macrophages in diverse phases of skin repair. J Immunol
184:3964-3977.

146.

Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S,
Lang R, Iredale JP. 2005. Selective depletion of macrophages reveals distinct, opposing
roles during liver injury and repair. J Clin Invest 115:56-65.

147.

Munder M, Eichmann K, Moran JM, Centeno F, Soler G, Modolell M. 1999.
Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic
cells. J Immunol 163:3771-3777.

148.

De Brauwer EI, Jacobs JA, Nieman F, Bruggeman CA, Drent M. 2002.
Bronchoalveolar lavage fluid differential cell count. How many cells should be counted?
Anal Quant Cytol Histol 24:337-341.

117

149.

Bedoret D, Wallemacq H, Marichal T, Desmet C, Quesada Calvo F, Henry E,
Closset R, Dewals B, Thielen C, Gustin P, de Leval L, Van Rooijen N, Le Moine A,
Vanderplasschen A, Cataldo D, Drion PV, Moser M, Lekeux P, Bureau F. 2009.
Lung interstitial macrophages alter dendritic cell functions to prevent airway allergy in
mice. J Clin Invest 119:3723-3738.

150.

Rose S, Misharin A, Perlman H. 2012. A novel Ly6C/Ly6G-based strategy to analyze
the mouse splenic myeloid compartment. Cytometry A 81:343-350.

151.

Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM. 2010. Inhibition
of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell
recruitment. Proc Natl Acad Sci U S A 107:8363-8368.

152.

Cappuccini F, Eldh T, Bruder D, Gereke M, Jastrow H, Schulze-Osthoff K, Fischer
U, Kohler D, Stuschke M, Jendrossek V. 2011. New insights into the molecular
pathology of radiation-induced pneumopathy. Radiother Oncol 101:86-92.

153.

Chiang CS, Liu WC, Jung SM, Chen FH, Wu CR, McBride WH, Lee CC, Hong JH.
2005. Compartmental responses after thoracic irradiation of mice: strain differences. Int J
Radiat Oncol Biol Phys 62:862-871.

154.

Zaynagetdinov R, Sherrill TP, Kendall PL, Segal BH, Weller KP, Tighe RM,
Blackwell TS. 2013. Identification of myeloid cell subsets in murine lungs using flow
cytometry. Am J Respir Cell Mol Biol 49:180-189.

155.

Gordon S, Taylor PR. 2005. Monocyte and macrophage heterogeneity. Nat Rev
Immunol 5:953-964.

156.

Wu G, Morris SM, Jr. 1998. Arginine metabolism: nitric oxide and beyond. Biochem J
336 ( Pt 1):1-17.

118

157.

Laskin DL, Sunil VR, Gardner CR, Laskin JD. 2011. Macrophages and tissue injury:
agents of defense or destruction? Annu Rev Pharmacol Toxicol 51:267-288.

158.

Zhang H, Han G, Liu H, Chen J, Ji X, Zhou F, Zhou Y, Xie C. 2011. The
development of classically and alternatively activated macrophages has different effects
on the varied stages of radiation-induced pulmonary injury in mice. J Radiat Res 52:717726.

159.

Mosser DM. 2003. The many faces of macrophage activation. J Leukoc Biol 73:209212.

160.

Gordon S, Martinez FO. 2010. Alternative activation of macrophages: mechanism and
functions. Immunity 32:593-604.

161.

Morris SM, Jr. 2007. Arginine metabolism: boundaries of our knowledge. J Nutr
137:1602S-1609S.

162.

Ao X, Zhao L, Davis MA, Lubman DM, Lawrence TS, Kong FM. 2009. Radiation
produces differential changes in cytokine profiles in radiation lung fibrosis sensitive and
resistant mice. J Hematol Oncol 2:6.

163.

Wang XP, Chen YG, Qin WD, Zhang W, Wei SJ, Wang J, Liu FQ, Gong L, An FS,
Zhang Y, Chen ZY, Zhang MX. 2011. Arginase I attenuates inflammatory cytokine
secretion induced by lipopolysaccharide in vascular smooth muscle cells. Arterioscler
Thromb Vasc Biol 31:1853-1860.

164.

Droke EA, Hager KA, Lerner MR, Lightfoot SA, Stoecker BJ, Brackett DJ, Smith
BJ. 2007. Soy isoflavones avert chronic inflammation-induced bone loss and vascular
disease. J Inflamm (Lond) 4:17.

119

165.

Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C,
Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G. 2007. PPARgamma
activation primes human monocytes into alternative M2 macrophages with antiinflammatory properties. Cell Metab 6:137-143.

166.

Wang N, Liang H, Zen K. 2014. Molecular mechanisms that influence the macrophage
m1-m2 polarization balance. Frontiers in immunology 5:614.

167.

Raffoul JJ, Banerjee S, Singh-Gupta V, Knoll ZE, Fite A, Zhang H, Abrams J,
Sarkar FH, Hillman GG. 2007. Down-regulation of apurinic/apyrimidinic endonuclease
1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in
vitro and in vivo. Cancer research 67:2141-2149.

168.

Martin M, Lefaix J, Delanian S. 2000. TGF-beta1 and radiation fibrosis: a master
switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys 47:277-290.

169.

Leask A, Abraham DJ. 2004. TGF-beta signaling and the fibrotic response. FASEB J
18:816-827.

170.

Santak G, Santak M, Forcic D. 2010. The role of interleukin-1beta and platelet-derived
growth factor-AB in antifibrosis mediated by native human interferon alpha. Surgery
148:490-498.

171.

Lemberger T, Desvergne B, Wahli W. 1996. Peroxisome proliferator-activated
receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev
Biol 12:335-363.

172.

Hart CM, Roman J, Reddy R, Sime PJ. 2008. PPARgamma: a novel molecular target
in lung disease. J Investig Med 56:515-517.

120

173.

Lakatos HF, Thatcher TH, Kottmann RM, Garcia TM, Phipps RP, Sime PJ. 2007.
The Role of PPARs in Lung Fibrosis. PPAR Res 2007:71323.

174.

Ricketts ML, Moore DD, Banz WJ, Mezei O, Shay NF. 2005. Molecular mechanisms
of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A
review. J Nutr Biochem 16:321-330.

175.

Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. 2003. Peroxisome
proliferator-activated receptors: regulation of transcriptional activities and roles in
inflammation. J Steroid Biochem Mol Biol 85:267-273.

176.

Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos
J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A,
Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. 2010. Meta-analysis of
concomitant versus sequential radiochemotherapy in locally advanced non-small-cell
lung cancer. J Clin Oncol 28:2181-2190.

177.

Guida C, Maione P, Rossi A, Bareschino M, Schettino C, Barzaghi D, Elmo M,
Gridelli C. 2008. Combined chemo-radiotherapy for locally advanced non-small cell
lung cancer: current status and future development. Crit Rev Oncol Hematol 68:222-232.

178.

Lo SS, Sahgal A, Chang EL, Mayr NA, Teh BS, Huang Z, Schefter TE, Yao M,
Machtay M, Slotman BJ, Timmerman RD. 2013. Serious complications associated
with stereotactic ablative radiotherapy and strategies to mitigate the risk. Clin Oncol (R
Coll Radiol) 25:378-387.

179.

Soliman H, Cheung P, Yeung L, Poon I, Balogh J, Barbera L, Spayne J, Danjoux C,
Dahele M, Ung Y. 2011. Accelerated hypofractionated radiotherapy for early-stage nonsmall-cell lung cancer: long-term results. Int J Radiat Oncol Biol Phys 79:459-465.

121

180.

Videtic GM, Stephans KL. 2010. The role of stereotactic body radiotherapy in the
management of non-small cell lung cancer: an emerging standard for the medically
inoperable patient? Curr Oncol Rep 12:235-241.

122

ABSTRACT
SOY ISOFLAVONES MEDIATE RADIOPROTECTION OF NORMAL LUNG TISSUE
BY MODULATING THE RADIATION-INDUCED INFLAMMATORY RESPONSE
by
LISA M. ABERNATHY
August 2015
Advisor: Dr. Gilda Gali Hillman
Major: Immunology and Microbiology
Degree: Doctor of Philosophy

Radiation-induced lung injury (RILI) is caused by an early inflammatory process
triggered by damage to lung parenchyma, epithelial cells, vascular endothelial cells and stroma.
Initially, oxidative injuries after radiation induce altered expression of pro-inflammatory
cytokines. Infiltrating inflammatory cells are stimulated and activated, producing additional
mediators, resulting in a cytokine cascade. The expansion and perpetual activation of
inflammatory cells, as well as lung parenchyma, lead to clinical pneumonitis. Activated cells
produce molecular mediators and growth factors that affect the proliferation and gene expression
of lung fibroblasts. This process leads to increased collagen synthesis and deposition, eventually
leading to the development of lung fibrosis. These adverse events after radiotherapy affect
patients’ breathing and their quality of life. Various strategies to decrease the extent of
pneumonitis have been investigated but need further research efforts.
We have previously demonstrated in mice receiving a single high dose of thoracic
irradiation that supplementation with a mixture soy isoflavones (genistein, daidzein, and
glycitein) has the dual capability of protecting normal lung tissue from radiation injury while
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simultaneously enhancing radiation damage in the tumor. However, mechanisms of
radioprotection by soy isoflavones in normal tissues remained to be elucidated. We hypothesized
that soy isoflavones mediate radioprotection via the modulation of radiation-induced
inflammatory processes involving macrophages, neutrophils, and myeloid-derived suppressor
cells.
The major findings of this work suggest that soy isoflavones can inhibit inflammatory
responses triggered by a single dose of thoracic irradiation in the lung, including NF-κB and proinflammatory cytokine production. We reveal that soy isoflavones inhibit the infiltration and
activation of macrophages and neutrophils in the lung induced by radiation. Radiation induced a
pro-inflammatory M1 macrophage phenotype in lungs, while mice receiving soy isoflavones and
radiation switched to an anti-inflammatory M2 macrophage subtype. Soy isoflavones had a
protective effect on regulatory interstitial macrophages (IM) after irradiation, while inhibiting
alveolar macrophage (AM) infiltration and activation induced by radiation. Interestingly, we
show that soy isoflavones promote granulocytic myeloid-derived suppressor cells that express
Arg-1 after radiation, resulting in subsequent downregulation inflammatory mediators. These
data indicate that lung radioprotection by soy isoflavones may occur via the modulation of
cellular and molecular mediators involved in the inflammatory response induced by radiation.
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